A Novel Immunostimulatory Platform for Amplifying the Abscopal Response Rates of Radiation Therapy by Paez, Patrick A
Virginia Commonwealth University 
VCU Scholars Compass 
Theses and Dissertations Graduate School 
2021 
A Novel Immunostimulatory Platform for Amplifying the Abscopal 
Response Rates of Radiation Therapy 
Patrick A. Paez 
Virginia Commonwealth University 
Follow this and additional works at: https://scholarscompass.vcu.edu/etd 
 Part of the Immunotherapy Commons, and the Translational Medical Research Commons 
 
© The Author 
Downloaded from 
https://scholarscompass.vcu.edu/etd/6747 
This Dissertation is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It 
has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars 




©Patrick A. Paez, August 2021 






















A Novel Immunostimulatory Platform for Amplifying the Abscopal Response 
Rates of Radiation Therapy 
A Thesis submitted in partial fulfillment of the requirements for the degree of Doctor of 




PATRICK A. PAEZ 
MASTER OF SCIENCE, VIRGINIA COMMONWEALTH UNIVERSITY, 2016 




Director: XIANG-YANG WANG, PH.D. 
PROFESSOR, DEPARTMENT HUMAN AND MOLECULAR GENETICS 
 
 














Table of Contents 
Acknowledgements ......................................................................................................... v 
List of Abbreviations ....................................................................................................... vii 
ABSTRACT .....................................................................................................................ix 
INTRODUCTION ............................................................................................................. 1 
A Historic Review and Rationale for Heat Shock Protein Cancer Vaccines ................. 1 
Historical Tumor-derived Hsp for Cancer Vaccination ................................................. 3 
Reconstitution of Hsp-TAA Complexes for Cancer Immunotherapy ............................ 4 
Immunostimulatory Features of Hsp ............................................................................ 8 
Scavenger Receptors and Hsp in Immune Modulation .............................................. 10 
Clinical Trials of Hsp-based Cancer Vaccines ........................................................... 15 
Next-generation Hsp-based Immunotherapy ............................................................. 17 
RT and Immune Activation ......................................................................................... 20 
Immune Targeting of Hsp for Enhanced RT............................................................... 22 
Head and Neck Squamous Cell Carcinoma (HNSCC) Application ............................ 28 
Next Generation Hsps Cancer Vaccines may Improve Clinical Response Rates ...... 31 
Copyright Disclaimer .................................................................................................. 33 
METHODS .................................................................................................................... 33 
Animals and Murine Cell Lines ................................................................................... 33 
Generation of Replication Deficient Adenovirus ......................................................... 34 
In vivo Tumor and Immune Neutralization Studies ..................................................... 35 
In vivo Stereotactic Radiation..................................................................................... 35 
Flow Cytometry and ELISA ........................................................................................ 36 
Quantitative PCR Analysis (qPCR) ............................................................................ 37 
Statistical Analysis ..................................................................................................... 37 
RESULTS ...................................................................................................................... 38 
Ad. Flagrp170 Intratumoral Injections Potentiate RT, Synergizing to Promote 
Antitumor Immunity. ................................................................................................... 38 
Flagrp170 Promotes Efficient Antigen Presentation Cell Priming and Activation in 
Draining Lymph Nodes, 16-hours post-Vaccination. .................................................. 39 
Radiation Therapy Combination Conferred Protection through Flagrp170, Improves 
Survival and Tumor Re-occurrence Risk. .................................................................. 40 
Mechanisms of Tumor Rejection in the SCC VII Model post-Flagrp170 Treatment ... 41 
iv 
 
Potentiation of the Abscopal Effect with Flagrp170 Treatment and Radiation Therapy 
Provides Improved Antitumor Immunity at Distant and Untreated Sites. .................... 41 
MOC II HNSCC metastatic model controlled via Flagrp170 mediated abscopal effect
 ................................................................................................................................... 43 
Flagrp170s Control of the B16 Melanoma Lung Metastasis Model ............................ 43 
DISCUSSION ................................................................................................................ 47 
The Double-edged Sword of RT ................................................................................ 47 
Immunological Conferred Abscopal Response and Protection via Flagrp170 and RT 
Combination Treatment ............................................................................................. 49 
Flagrp170s Potential for Clinical Translation and Efficacy in HNSCC and Future 
Directions ................................................................................................................... 51 
Figure 1. Flagrp170 potentates the danger signals from radiation therapy (RT), 
synergizing to promote anti-tumor immunity. ................................................................. 56 
Figure 2. Flagrp170 promotes efficient APC priming and activation in draining lymph 
nodes 16hrs post-vaccination. ....................................................................................... 60 
Figure 3. Radiation Alone and the Combination Treatment of Radiation and Flagrp170 
Group Provided Protection in Established (5-6mm) SCC VII Tumors. .......................... 64 
Figure 4. Head and neck tumor cells infected with Ad. Flagrp170 promotes immunity to 
tumor challenges via CD4 effector function. .................................................................. 65 
Figure 5. SCC VII Contralateral tumor Model: Combination treatment of Flagrp170 and 
RT therapy provides improved antitumor immunity at distant and metastatic sites. ...... 71 
Figure 6. Combination treatment of Flagrp170 and RT therapy provides improved anti-
tumor immunity against a naturally metastatic HNSCC model. ..................................... 74 
Figure 7. B16 Melanoma Primary and Lung Metastatic Model ...................................... 76 
Figure 8. Combination Therapy Induces Increased T-cell Activation Concomitantly with 
Strong Inhibitory Signals at the Tumor Site. .................................................................. 78 
Figure 9. Metastatic Site Experienced Increased Immune Stimulation and while 
Undergoing Robust Inhibitory Signals. .......................................................................... 80 
REFERENCES .............................................................................................................. 81 










I would like to dedicate the work presented in this thesis to the memory of my mother 
Patricia Maria Paez (May, 7th, 1960 – September, 26th, 2018). She lived a life of 
courage and raised her children as a living example. Her lessons of kindness and 
bravery are still being taught through the memories long after her passing to both my 
sister and I. She exemplifies the notion that not even death can stop the love of a parent 
for their children. The memories of her words of encouragement and belief in me were 
and will remain a constant motivating force to persevere in my endeavors.  
 
I would like to thank my family and my wife for their support during the five years of 
training. In particular their unwavering support throughout the countless hours spent 
away from them while conducting experiments in the lab, studying, or drifting into bouts 
of data analysis. To my wife, thank you for always supporting me through the difficult 
times. This is a journey was made easier because we did it together, thank you for 
being my partner in life. To my sister, thank you for always being my personal 
soundboard and litmus test through this difficult period. Your ability to evaluate 
situations from your experiences as an executive leader has been indispensable in this 
process. To my father, thank you for the love of medicine, it helped carve my path in the 
world, and to see the through periods of fog in this long academic journey. I would also 
like to acknowledge our dog Jagger, who passed away after 14 wonderful years. I know 
you are being a good boy, eating all the bread you want at the rainbow bridge in heaven 
next to mom. To our newest pup Sarge, thank you for being one of the best at home co-
workers through the pandemic, your kind energetic humor came to me a time when I 
vi 
 
really needed it. You helped me push through the many struggles I encountered. To my 
daughter Amelia Grace Paez, I love you already, and I cannot wait to meet you. 
 
I would like to thank several members in my lab. Dr. Guo, you have been at my side at 
the bench for five years and I could not have imaged doing this work without you. Dr. 
Liu, you joined the lab at a difficult time, the knowledge and expertise you brought to the 
lab helped us make progress on this project. I would also like to thank Dr. John Ryan 
who was my mentor during the Masters program, and a member of my PhD committee. 
I will always be gratefully indebted to his investment in my academic and professional 
development. Many years ago, he was the first professor who saw my potential “as a 
diamond in the rough” and in turn pushed me to pursue my dreams. I would also like to 
thank Dr. Andrew Poklepovic for his clinical expertise and unfaltering enthusiasm for our 
passion in developing new therapeutic interventions in the laboratory. Thank you for 
believing in our labs work and helping us fulfill our dreams of introducing our therapeutic 
agents into clinic. Finally, I would like to thank Dr. Xiang-Yang Wang for his mentorship 
and providing me with wonderful opportunities over the past five years. Our task was 
not an easy one, but, the development of new treatments for cancer patients is one of 
the worthiest burdens to shoulder. I look forward to our future work together, bringing 






List of Abbreviations 
 
 
Hsp – Heat shock protein 
 
TAA – Tumor associated antigen 
 
TSA – Tumor specific antigen  
 
HER2/Neu – Human epidermal growth factor receptor 2 
 
CTA’s – Cancer testis antigens 
 
MAGE-1 -Melanoma-associated antigen 1 
 
NY-ESO-1 -New York esophageal squamous cell carcinoma 1 
 
SSX - Synovial sarcoma X breakpoint 
 
CAGE – Cancer-associated antigen gene  
 
CTL – Cytotoxic lymphocyte  
 
TRP2 - Tyrosinase-related protein-2 
 
Gp100 – Glycoprotein 100 
 
HLA – Human leukocyte antigen 
 
MHC -  Major histocompatibility complex 
  
TLR – Toll-like receptors 
 
DAMP – Danger associated molecular patterns 
 
PAMP – Pathogen associated molecular patterns 
 
APCs – Antigen presenting cells 
 
DCs – Dendritic cells  
 
SRs – Scavenger receptors  
 
CLEC – C-type lectin-like receptors  
 
LOX-1 - Lectin-like oxidized LDL receptor 1 
viii 
 
GM-CSF - Granulocyte-macrophage colony stimulating factor 
 
IFN – Interferon (α,β,γ)  
 
NK cells – Natural Killer cells 
 
RT – Radiation therapy 
 
MDSCs – Myeloid derived suppressor cells  
 
ICD – Immunogenic cancer cell death 
 
dsDNA – double stranded deoxyribonucleic acid  
 
CTLA-4 - cytotoxic lymphocyte antigen-4 
 
PD-1 – Program cell death protein  
 
PDL1 – Program death ligand 1 
 
ICB – Immune checkpoint blockade  
 
HNSCC – Head and neck squamous cell carcinoma  
 
HPV – Human papilloma virus 
 
CPS – Composite positive score 
 
SARRP – Small animal radiation research platform 
 
OVA – Ovalbumin  
 
ELISA – Enzyme-linked immunosorbent assay 
 
WCL – Whole cell lysate 
 
TDLNs – Tumor draining lymph nodes 
 







Radiation therapy (RT) is one of the primary treatment modalities for head and neck 
squamous cell carcinoma (HNSCC). At the time of diagnosis two-thirds of HNSCC 
patients have local-advanced disease and 50-60% of these patients will experience a 
local-regional or metastatic relapse within three years. Improving the immunogenic 
response of RT may help address this clinical problem. However, current RT regimens 
have failed to reliably generate robust antitumor immunity as evidenced by the rarity of 
clinical abscopal responses. Recently we engineered a chimeric fusion molecule called 
Flagrp170, a novel immunostimulatory agent highly capable of promoting antigen 
presentation and T-cell activation. We hypothesize that the combination of RT and 
Flagrp170 provides superior immunogenic signals producing effective and durable 
antitumor immunity against HNSCC. We report that administration of Flagrp170 to the 
tumor sites upon RT using a small animal radiation research platform (SARPP) results 
in potent activation of antigen-presenting cells, increased functionality of tumor-
infiltrating T-cells, and systemic immune augmentation. Additionally, the combination 
treatment is able to reduce the dose of RT required for tumor control and protects 
previously cured animals from subsequent tumor re-challenge. Finally, the combination 
treatment can successfully control the contralateral untreated tumors, supporting the 
superior activity of Flagrp170 in potentiating abscopal responses of RT. Our data 
suggest that the Flagrp170 may be used to enhance immunogenic cancer cell death in 






A Historic Review and Rationale for Heat Shock Protein Cancer Vaccines 
 
Heat shock proteins (Hsp) are a set of highly conserved molecules common to all 
kingdoms of life. The heat shock response that is associated with induction of Hsp was 
first discovered unexpectedly in 1962 by Ferruccio Ritossa when cells derived from 
Drosophila salivary glands were accidentally exposed to hyperthermic conditions (1). A 
striking pattern of polytene chromosome puffs were described in these cells and later 
identified as the transcription sites of the common “heat shock response” genes (2). 
Based on their molecular sizes, mammalian Hsp are categorized into several major 
families, including small Hsp (e. g., Hsp27), the Hsp40, the Hsp60, the Hsp70, the 
Hsp90, and the large Hsp (e.g., Hsp110, glucose-regulated protein 170 or Grp170). In 
addition to hyperthermia, Hsp expression can be induced by a broad range of cellular 
stressors including oncogenic stress, the accumulation of unfolded proteins, hypoxia, 
oxidative stress, and the genotoxic stress caused by ionizing radiation or 
chemotherapeutic drugs (3, 4). 
 
Hsp are constitutively expressed at basal levels and primarily function as 
intracellular chaperones in the folding, assembly, transportation, and degradation of 
misfolded proteins. These functions are necessary for the recovery of protein 
homeostasis in response to cellular stressors (5). However, extensive studies over the 
past twenty years indicate that, upon release into the extracellular environment, Hsp 
can assume an immunostimulatory role by facilitating the delivery of multiple 
intracellular antigens, sometimes referred to as an ‘antigenic fingerprint’ to specialized 
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antigen-presenting cells (APCs). Hsp can also act as damage-associated molecular 
patterns (DAMPs) to promote immune activation. This interaction between extracellular 
Hsp and the immune system is believed to represent an endogenous and ancient form 
of immune surveillance (6, 7). This also provides an immunological basis for utilizing 
cancer cell-derived or reconstituted Hsp-antigen complexes to elicit potent antitumor 
immunity for cancer immunotherapy (8, 9). 
The ‘abscopal effect’ is a rare immune phenomenon wherein an adaptive 
antitumor immune response generated by radiation therapy (RT) results in the inhibition 
of metastases outside of the field of radiation (10). In the past two decades, an ever-
growing body of evidence suggests that RT also has potent local immunomodulatory 
effects (11-17). As these effects have become more appreciated, the clinical potential of 
combining RT and immunotherapy to immunologically sensitizing irradiated tumors to 
RT has become an active area of research (18-25). Next-generation immunotherapies 
such as Hsp vaccines and immune checkpoint blockade (ICB) may be strategically 
developed to amplify RT-associated ‘abscopal’ effect and to generate systemic 
antitumor immunity capable of controlling metastatic diseases. In this thesis, we will 
discuss the current understanding of the immunostimulatory features of Hsp, their 
preclinical and clinical utilizations to date, as well as their potential for modulation of 
tumor microenvironment which can be exploited to synergize with RT to achieve lasting 




Historical Tumor-derived Hsp for Cancer Vaccination 
 
Different subcellular compartments have their own dedicated species of Hsp. Under 
physiological conditions, Hsp70, Hsp90 and Hsp110 are localized in the nucleus or 
cytosol, while their corresponding homologues Grp78, Grp94 and Grp170 are 
endoplasmic reticulum (ER) residents (2). While Grp are functionally and structurally 
related to Hsp, they are induced by different sets of stressors including chronic hypoxia, 
calcium ionophores, and inhibition of glycosylation (26, 27). The nomenclatures of Hsp 
and Grp were derived from their original discoveries. However, these two terms have 
been used interchangeably in some cases due to the fact that both are essential integral 
components of cellular stress responsive network. Intracellular Hsp and Grp play a 
cytoprotective role in normal and cancerous cells by interacting with their client proteins, 
minimizing stress-induced protein denaturation, and promoting cell survival. As a result, 
Hsp overexpression has been shown to facilitate tumor development and to positively 
correlate with poor prognosis in multiple cancers such as ovarian, prostate, breast, and 
colorectal cancer (7, 28-30).   
The key chaperoning function of Hsp is facilitating the correct folding of nascent 
or misfolded proteins via the binding of hydrophobic regions exposed to the cytosol. 
This function also prevents the aggregation of misfolded proteins in cancer cells which 
may otherwise accumulate as a result of oncogenic stress, leading to apoptosis. This is 
also believed to represent a major mechanism by which Hsp overexpression confers 
tumor resistance to chemotherapy or RT (31-33) Additionally, other cytoprotective 
activities of Hsp have also been elucidated. For instance, Hsp were shown to bind and 
neutralize chemotherapeutic agents, free radicals, and cytotoxic cytokines such as 
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tumor necrosis factor (TNF)α/β (34-37). Given that Hsp often interact with several 
oncogenic drivers of tumorigenesis and that Hsp protect cancer cells from the cytotoxic 
effects of cancer therapeutics, a large number of small molecule inhibitors of Hsp are 
being tested as potential therapeutic agents (38). 
Despite the well documented tumor-promoting properties of Hsp, other 
investigations demonstrate that tumor-derived Hsp carry an array of antigenic tumor-
associated peptides and can be utilized to generate potent antitumor responses with 
lasting immunological memory against cancers (39-43). In addition to the conventional 
Hsp prepared from cancer cell lines, treatment with large Hsp such as Hsp110 and 
Grp170 derived from autologous tumors (e.g., methylcholanthrene-induced 
fibrosarcoma, colon carcinoma, and melanoma) also elicit a robust T-cell-mediated 
antitumor immunity (44, 45). This immunotherapeutic effect has been attributed to the 
ability of Hsp to efficiently chaperone tumor-associated antigens (TAAs) and to enhance 
the cross-priming of antigen-specific T lymphocytes (46-48)   
 
Reconstitution of Hsp-TAA Complexes for Cancer Immunotherapy 
 
While autologous Hsp vaccines carry an immunological “fingerprint” of the patient’s 
tumor and represent a personalized medicine, its clinical use is often limited by the 
needs for excised patient specimen and the complex ex vivo procedure of vaccine 
preparation. The lack of antigenic information on targeted TAAs also reduces immune 
monitoring capability in the clinic (49-51). To circumvent these limitations, we developed 
a chaperoning technology to reconstitute Hsp-TAA complexes by taking advantage of 
the superior protein or polypeptide-holding capacity of the large Hsp (i.e., Hsp110, 
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Grp170) (45, 52-56). The clinically relevant TAAs that have been tested using this 
recombinant chaperone vaccine include melanoma antigen glycoprotein 100 (gp100), 
breast cancer antigen human epidermal growth factor receptor 2 protein (i.e., 
HER2/Neu), and renal cell carcinoma antigen carbonic anhydrase IX. In one study, 
immunization with Hsp110 coupled to human HER2/neu antigen successfully 
suppressed the development of murine spontaneous breast cancer (53). 
This recombinant approach has the advantages of not requiring patient specimen 
as well as easy bulk preparation of the “off-the-shelf” products for clinical applications. 
This vaccine can be used in an adjuvant setting to treat patients with completely 
resected disease, or those at a high risk for recurrence. However, the antigenic 
repertoire from the targeted TAAs may not be sufficient for eradicating heterogeneous 
cancer cells in solid tumors, and tumors may become resistant to single-valent 
vaccination by simply downregulating the target antigen. Nonetheless, this synthetic 
approach can serve as a building block to formulate recombinant chaperone vaccines 
concurrently targeting multiple TAAs to augment multivalent T-cell responses, which 
can help minimize cancer escape. Using the B16 melanoma model, our lab 
demonstrated that the combination of melanoma antigens tyrosinase-related protein 2 
and gp100 complexed with Grp170 or Hsp110 provided better antitumor protection as 
compared to either of the single antigen-targeted vaccine (57).  
TAAs (e.g., HER2/Neu) are antigens that are often highly expressed by tumors 
and are not strictly unique epitopes to tumor tissues. Another group of tumor antigens 
are those genes whose expression is normally restricted to a particular tissue or period 
of embryonic development. Inappropriate acquisition of expression of these genes may 
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impart a degree of “stemness” to cancer cells, making them more capable of rapid 
division, invasion, and avoiding apoptosis. These antigens are collectively referred to as 
cancer testis antigens (CTAs), which include MAGE-1, NY-ESO-1, SSX, and CAGE 
(58). However, TAAs including CTAs are also expressed in normal tissues and 
autoimmune complications from immunotherapy can occur. One recent example of a 
severe adverse event occurred in a clinical trial of chimeric antigen receptor-T-cell 
therapy targeting the MAGE-3. Two out of nine patients that received this treatment 
developed periventricular necrotizing leukoencephalopathy and subsequently lapsed 
into comas and died. This study suggests that the immunotoxicity was likely due to the 
unforeseen expression of the targeted isoform in the brain (59). Although reports of 
Hsp-reactive autoantibodies have been detected in certain strains of mice, no 
autoimmunity-related adverse events have been reported to date in clinical trials 
utilizing Hsp vaccinations (49, 60). Other major antigen targets that should be 
considered for immunotherapy with recombinant Hsp vaccinations are neoantigens 
resulting from oncogenic mechanisms, such as E6 and E7 proteins found in human 
papillomavirus-driven head and neck cancers, and the BCR-ABL fusion protein from 
chromosome rearrangement that is common in chronic myeloid leukemia. These unique 
proteins with neoepitopes not found elsewhere in the body are referred to as tumor-
specific antigens (TSAs). They represent attractive targets for Hsp vaccination due to 
their diminished risk for off-target autoimmunity, and the chance for a potent immune 
response not hindered by tolerogenic processes in the body. Indeed, recent studies 
suggested a strong correlation between patient response to immune checkpoint 
inhibitors and the presence of tumor microsatellite instability. It is hypothesized that the 
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microsatellite instability is a mechanism for rapid chromosomal rearrangement 
responsible for the production of neoantigens (61, 62). However, not all cancers 
express highly immunogenic neoepitopes available for generating specific antitumor 
immune responses.  
In addition to full-length protein antigens, antigenic peptides can also be 
complexed to Hsp for cancer vaccination. For example, the large Hsp-TRP2175-192 
peptide complex readily induced a potent TRP2175-192 cytotoxic T-lymphocyte (CTL) 
response. However, the protective antitumor efficacy induced by such a peptide-
targeted vaccine is much weaker than that achieved by the chaperone vaccine targeting 
the TRP2 protein (57). This superiority of protein antigen-targeted vaccination may be 
due to multiple antigenic epitopes inherent to a whole protein, providing APC many 
opportunities to produce a peptide that will fit into its major histocompatibility complex 
(MHC) and generating T helper signals for optimized or sustained CTL activation. 
Considering the heterogeneity of human MHC allotypes, possible human leukocyte 
antigen (HLA) restrictions as well as the differences between individual peptides, 
vaccination with large Hsp-protein antigen complexes may prove to be more effective 
for a wider variety of patients.  
Targeting single antigen or epitope clearly has its disadvantage in the treatment 
of heterogenous cancer cell populations. Advances in next generation sequencing and 
bioinformatics are now beginning to mitigate some of the shortcomings associated with 
using recombinant Hsp-TAA complexes and the ambiguity of selecting peptide targets 
for different cancers and patients. There are several in silico prediction tools for tumor 
protein or peptide sequencing, aiding in predicting HLA binding of specific tumor 
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antigens, and T-cell receptor sequencing for analysis of the T-cell antigenic repertoire 
after immunotherapeutic interventions (63). 
 
Immunostimulatory Features of Hsp 
 
Clinically significant antitumor immunity is dependent upon the activation of tumor-
specific CD8+ T-cells by APCs that have taken up TAAs. MHC I molecule is present on 
all nucleated cells and functions to randomly present endogenous peptides for the 
purpose of intracellular immune surveillance. MHC II molecule, on the other hand, is 
expressed only on APCs. It functions to present exogeneous peptides from 
phagocytosed pathogens and dying cells to other cells of immune system. The peptide 
binding cleft of MHC I is smaller (8-11 amino acids) and it is restricted to interactions 
with the T-cell receptor (TCR) of CD8+ CTLs (64). MHC II, on the other hand, has a 
larger peptide binding groove (13-17 amino acids), and is restricted to interactions with 
CD4+ helper T-cells. ‘Cross-presentation’ is the less-understood process by which 
internalized antigens from the extracellular environment, typically loaded onto the MHC 
II complex, are instead shuttled to a pathway that results in formation of MHC I 
complexed with processed peptide epitopes for priming CD8+ T-cells. This cross-
priming process greatly facilitates the generation of antitumor CD8+ T-cells by allowing 
their direct activation in the lymph node by APCs that have captured exogenous TAAs, 
such as the case of cancer vaccination with tumor-derived Hsp preparations (64). 
Indeed, one of the critical features of Hsp in cancer immunotherapy is their capability to 
introduce associated TAAs into the endogenous antigen-processing pathways for cross-
presentation by APCs, e.g., dendritic cells (DCs) (65-67). 
9 
 
The mechanism underlying Hsp-enhanced antigen cross-presentation is not well 
understood. It has been shown that Grp170 can direct the chaperoned peptide into the 
Rab5+EEA1+ static early endosomes, where the peptides are loaded onto the recycling 
MHC-I molecules (68). Our study of the trafficking pathway of Grp170 complexed with 
melanoma antigen gp100 revealed that the internalized chaperone complex gained 
access to the ER following uptake by DCs (69). Strikingly, the Grp170-facilitated antigen 
cross-presentation requires the ER-associated protein degradation pathway involving 
Sec61, a protein quality control machinery in the ER, which targets antigen for 
proteasome-mediated degradation in the cytosol and integration into the conventional 
MHC I-restricted antigen-processing pathway. Our observation also suggests that 
Grp170 chaperoning allows protein antigen to escape from lysosomal degradation and 
facilitate its entry into the ER from the early endosomes, possibly through a “ER-
endosome fusion” structure. However, additional studies are necessary to fully define 
the exact role of Hsp in antigen cross-presentation. 
In addition to their cross-presentation promoting activity, Hsp upon release from 
injured or stressed cells to the extracellular milieu are believed to serve as ‘danger’ 
signals or DAMPs to alert the immune system. Several studies suggest that Hsp bind to 
toll-like receptor (TLR) 2/4 on the surface of APCs, stimulating the NF-ᴋB pathway 
necessary for the activation of APCs and for the production of pro-inflammatory 
cytokines. Specifically, binding of Hsp to DCs or macrophages increases their 
expression of maturation markers and co-stimulation molecules such as CD80, CD86 
and CD40 as well as the pro-inflammatory cytokines IL-6 and TNF-α (70). The 
expression of these co-stimulatory molecules represents the additional signals required 
10 
 
to prime antitumor T-cells and to prevent immune tolerance during antigen presentation 
(71-74). However, other studies suggest that contamination of recombinant Hsp with 
lipopolysaccharide, the natural ligand for TLR2/4, may explain the reported Hsp-
associated TLR activation (75). While this confounding variable has complicated the 
issue of whether Hsp themselves retain innate-stimulatory activity, additional studies 
using different experimental models instead of Hsp-derived from bacteria protein 
expression systems continue to support this intrinsic immunostimulatory feature in Hsp 
(76, 77). Further supporting evidence demonstrates that cancer cells engineered to 
secrete GRP170 were more efficient than unmodified cells in stimulating DCs to 
produce TNF-α (78). It has also been reported that high doses of Hsp-TAA complexes 
are capable of inducing immune-tolerance by expansion of regulatory T-cells, which 
suggests that any endogenous DAMP activity carried by Hsp may be insufficient to 
stimulate APC activity on their own (79, 80). Therefore, Hsp-based antitumor 
vaccination may be considerably enhanced by the integration of pathogen-associated 
molecular patterns (PAMPs) or microbial signals capable of activating the TLRs or other 
signaling pattern recognition receptors on APCs.  
 
Scavenger Receptors and Hsp in Immune Modulation 
 
Scavenger receptors (SRs) were originally defined by their ability to bind to modified 
lipoproteins and facilitate their removal from the extracellular environment. However, 
members of this family of receptors can bind to a wide array of non-self or self-ligands, 
including lipopolysaccharide, lipoteichoic acid, double stranded DNA (dsDNA), Hsp, 
dying cells or apoptotic bodies. SRs are primarily expressed on APCs such as myeloid 
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cells but are also reported to be present on endothelial cells (ECs) and fibroblasts (81-
83). SRs can be categorized into multiple classes based on their sequence similarities 
or shared structural features, but there is little or no sequence homology between the 
different classes of SRs (84). Early studies support the important roles of SRs as major 
innate pattern recognition receptors in tissue homeostasis and host defense against 
microbial infection (81). Investigations of the binding structures of Hsp vaccines on the 
surface of APCs have led to the discovery of their previously unrecognized functions in 
mediating antigen uptake and cross-presentation, as well as myeloid cell polarization 
and APC activation (83). While SRs are required for recognizing, binding, and 
internalization of Hsp-TAA complexes, different SRs appear to have different levels of 
specificity for Hsp species and may control the fate of any TAAs to which they bind. 
Therefore, involvement of specific SRs in the uptake of different TAAs may have distinct 
immunological consequences, potentially determining the antitumor efficacy of Hsp-
based vaccination (83). 
Class A SRs are characterized by one or more collagen domains as well as a 
possible C type lectin (CLEC) and/or a type A scavenger receptor cysteine rich (SRCR) 
domain (81). Scavenger receptor A (SRA), also called macrophage scavenger receptor 
1 or CD204, is the prototypic member of this class. SRA is believed to bind ligands 
through its SRCR while its collagen domain is dedicated to mediating interactions with 
binding partners. Using in vitro systems, we and others have demonstrated that SRA is 
required for uptake of Hsp110, Grp94, and Grp170 by APCs and subsequent cross-
presentation of Hsp-associated antigens (85, 86). Unexpectedly, we found that genetic 
ablation of SRA in mice strongly promoted antitumor immune responses generated by 
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autologous tumor-derived Hsp, recombinant Hsp-antigen complex, or TLR4-targeting 
cancer vaccines, indicating an immunosuppressive role of SRA in antitumor immunity 
(87, 88). Further mechanistic studies reveal that SRA expression in DCs dampens their 
immunostimulatory function by interfering with the NF-B activation. This reduces 
expression of co-stimulatory molecules and pro-inflammatory cytokines or chemokines, 
thereby attenuating tumor-reactive CTL response in vivo (89-92). Not surprisingly, 
downregulation of SRA expression in DCs markedly improves the immunogenicity of 
DC-based vaccination and resultant antitumor immunity (93).  In addition, the overall 
level of this receptor in the tumor has been reported to correlate with poor prognosis in 
human cancer patients (83). Other than its role for negative regulation of DC function, 
this may also be due to its ability to contribute to macrophage M2 polarization through 
ER stress signaling or by its ability to sequester interferon regulatory factor 5, a master 
regulator of pro-inflammatory gene expression in myeloid cells (94, 95). While SRA on 
DCs or macrophages clearly presents an opportunity for immunotherapeutic targeting, 
the relevance of endothelial and fibroblast SR expression also deserves consideration 
due to the reports that these cell types can function to suppress antitumor immunity by 
directing deletion of antigen-specific CD8+ T-cells (82, 96).  
Lectin-like oxidized LDL receptor 1 (LOX-1), the only member of the class E SRs, 
has a single CLEC domain and is primarily expressed on ECs, B cells, macrophages, 
and DCs (81).  This SR appears to play an important permissive role in the antitumor 
activity of CD103+BATF3+ DCs and T-cell priming in response to Hsp70-TAA complexes 
or apoptotic bodies induced by radiation (97, 98). LOX-1 has been shown to bind to 
Hsp70 and direct their associated antigens to the endogenous cross-presentation 
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pathways. Furthermore, anti-LOX-1 antibodies inhibit Hsp70-TAA complex induced T-
cell mediated antitumor immunity. Although the data remains limited, LOX-1 may 
represent a preferable pathway for the processing of Hsp-TAA complexes to mount an 
antitumor CTL response. 
Scavenger receptor expressed by endothelial cells-I (SREC-I) is a member of 
class F SRs that often have multiple epidermal growth factor (EGF) and EGF-like 
domains (81). SREC-I can bind to multiple chaperones including Hsp70, Hsp90, 
Hsp110, Grp170, and calreticulin (86, 99-101). Additionally, SREC-I expression is 
elevated on DC exposed to Hsp70-TAA based vaccine. Whether this SR has a 
permissive or suppressive effect on antitumor immunity generated by Hsp-TAA has yet 
to be explored in a therapeutic setting in vivo. However, given its wide range of Hsp-
binding partners, exploring SREC-I function in the context of Hsp-based immunotherapy 
is an attractive future research direction. 
Stabilin-1 is a member of class H SRs that contain multiple EGF and EGF-like 
domains, a fasciclin-1 and LINK domains, and a hyaluronan- binding domain typical of 
proteins that interact with the extracellular matrix (81). Stabilin-1 is constitutively 
expressed on lymphatic ECs and tissue resident macrophages but can also be induced 
on vascular endothelial cells in response to inflammation. Stabilin-1 on APCs has been 
shown to bind to Hsp70-TAA complexes and to mediate their internalization (99). 
However, the overall effect of this SR on antitumor immunity induced by Hsp70-TAA 
vaccination is unclear. Interestingly, stabilin-1 knockout or blockade reinvigorates T-cell 
response to solid tumors by reducing tumor-infiltrating immunosuppressive cells and 
enhancing recruitment of effector T-cells (102). Other studies linked this SR to 
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mobilization of regulatory T-cells by ECs as well as the immunosuppressive function of 
tumor-associated macrophages (103, 104). Although its role in Hsp-based vaccination 
has not been thoroughly investigated, stabilin-1 has been implicated in multiple 
immunosuppressive processes of the cancer-immune cycle. Therefore, Hsp-based 
immunotherapy may benefit from blockade or pharmaceutical inhibition of this receptor.  
LDL receptor-related protein 1 (LRP1/CD91) is a type 1 transmembrane receptor 
that is expressed on the surface of APCs such as macrophages and DCs. Similar to 
SRs, CD91 partners with many different co-receptors on the cell surface to facilitate 
endocytosis of structurally diverse ligands and to modulate the resulting immune 
response. Unlike other endocytic receptors for Hsp, CD91 can directly transmit 
immunostimulatory signals upon phosphorylation of its cytoplasmic domain. Although 
the complete signaling apparatus associated with CD91 remains to be elucidated, 
engagement of this receptor results in immunostimulatory cytokine expression via the 
activation of NF-B and p38, as well as phosphorylation of ERK and PI3K (105-107).  
This receptor has been suggested to be a common receptor for Grp94/Gp96, Hsp90, 
Hsp70, and calreticulin, which is necessary for cross-presentation of tumor antigens 
chaperoned by these Hsp and can directly stimulate NF-B and p38 in response to its 
Hsp ligands (106). To what extent CD91 partners with other known Hsp receptors for 
modulation of Hsp-induced T-cell response is currently unknown. It is likely that other 
receptors also participate in this coordinated process, because Hsp stimulation of 
myeloid cells results in the production of cytokines not regulated by CD91.  
Although these SRs are identified as Hsp-binding molecules on APCs, the 
individual SRs appear to display distinctly different effects on antitumor immune 
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responses elicited by Hsp-based anticancer vaccination or possibly immunotherapy in 
general. Although the different classes of SRs are structurally unrelated, their ligand 
binding domains share a common motif: centrally located cationic clusters surrounded 
by anionic residues. This, along with the preference of many SRs to bind to anionic 
ligands, suggests that SR-ligand interactions are electrostatic in nature (81). In addition 
to allowing for ligand binding, the involvement of a specific SR during antigen uptake is 
likely to affect the trafficking and processing of antigens inside the cell. For instance, 
this can determine whether an internalized antigen carried by Hsp is silently degraded in 
the lysosomes or shuttled into endogenous antigen-processing pathways for cross-
presentation by MHC I molecules. Additionally, SRs have been demonstrated to alter 
the cytokine response of APCs to different antigens, making their potential impact on T-
cell differentiation and function especially relevant (106). The diversity of SR 
functionality may also be compounded by the fact that many SRs participate with other 
receptors in large signaling complexes termed “signalosomes.” This capacity for 
cooperative actions further enhances functional versatility of these receptors, making it 
possible for an individual SR to play different roles on the surface of various cell types 
(81). As a result, other than optimization of antigen presentation and APC activation, 
rational design of Hsp-based tumor vaccination requires careful consideration of their 
interactions with these receptors.  
 
Clinical Trials of Hsp-based Cancer Vaccines 
 
The promising preclinical results of Hsp-based immunotherapies have led to multiple 
clinical trials to date, some of which have yet to be completed and published. In a phase 
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II trial of autologous tumor-derived Grp94/Gp96-peptide vaccination (HspPC-96, 
Vitespen or Oncophage) paired with granulocyte-macrophage colony stimulating factor 
(GM-CSF) and interferon (IFN)-α for the treatment of metastatic melanoma, 11 of 18 
patients with measurable disease post-surgery showed disease stabilization. Addition of 
IFN-α and GM-CSF did not enhance the vaccine effects compared to vaccination alone 
(108). The autologous Grp94/Gp96-peptide complex vaccine has also been tested in a 
phase III trial for the treatment of stage IV melanoma patients. Results of the trial 
showed that there was no difference in overall survival between the standard of care 
and the Grp94/Gp96 vaccination. However, a more detailed patient subclassification 
revealed a survival benefit for the early-stage IV melanoma patients (M1a, distant skin, 
subcutaneous or nodal metastasis; M1b, lung metastasis) (109). This autologous 
Grp94/Gp96 vaccine was also recently tested in a phase II multi-center trial for treating 
patients with recurrent glioblastoma post-surgery. The treatment resulted in a median 
overall survival of 42.6 weeks, with 90.2% of patients surviving longer than 6 months, 
which is improved compared to historical controls (110). Currently, two randomized 
trials are open to assess survival in recurrent glioblastoma patients receiving the 
Grp94/Gp96 vaccine plus Bevacizumab or plus standard treatment (RT and 
temozolomide) vs. patients receiving Bevacizumab or standard treatment alone.  
The large Hsp110-gp100 protein antigen complex has also been investigated in a 
phase I trial through the National Cancer Institute Rapid Access to Intervention 
Development or RAID program. Patients with recurrent and advanced stage melanoma 
were vaccinated with different doses of recombinant human Hsp110-gp100 complex 
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vaccine as seen in the pre-clinical studies (45, 57). The immune correlative studies 
have been completed and are under review. 
An ex vivo Hsp70 activated NK-cell therapy was tested in a phase II trial for 
treatment of patients with non-small cell lung carcinoma who were refractory to cisplatin 
and RT. Patients in the trial first underwent leukapheresis to have their NK cells 
expanded and stimulated with Hsp70 peptide and low doses of IL-2 ex vivo, and then 
were re-infused with the activated NK cells. There was only moderate clinical activity 
observed, perhaps due to the advance stage of the disease. However, immunological 
activity was evident and generally well tolerated in all patients (111).  
Two ongoing clinical trials use allogenic injections of irradiated human lung 
cancer cell lines transfected to secrete Grp94/Gp96 (HS-110; viagenpumatucel-L) or 
OX40 antibodies (HS-130) with agonistic activity for co-stimulatory molecules on T-cells. 
In the current phase Ib/II (DURGA trial), HS-110, the allogenic cell line expressing 
Grp94/Gp96 will be irradiated and used to vaccinate patients in combination with ICB. 
The second clinical trial is testing the combined HS-110/HS-130 treatment for 
concurrent vaccination and co-stimulation.  
 
Next-generation Hsp-based Immunotherapy 
 
Although numerous studies have documented the intrinsic innate-immunostimulating 
property of Hsp, this effect in most cases is very modest and may not be adequate to 
efficiently mount an adaptive antitumor immune response. Given that pathogen-sensing 
signaling pathways in APCs are instrumental in bridging innate and adaptive immune 
responses, its use may aid in driving robust T-cell activation. Therefore, integrating 
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PAMPs into Hsp-based antigen delivery cargo could further promote immune activation 
(112). Recently, we engineered a chimeric Hsp molecule, termed Flagrp170, by fusing a 
defined NF-κB-stimulating sequence from the NLRC4 and TLR5 agonist flagellin to the 
chaperone GRP170. This molecular engineering takes advantage of the superior 
antigen-binding capacity of the large Hsp and the NF-κB-stimulating activity of microbial 
signal to create a next-generation Hsp-based immunotherapeutic agent with enhanced 
immunogenicity. This unique molecule in the form of protein or DNA can be used to 
develop multimodal immunotherapeutic applications, including recombinant chaperone-
TAA protein complex vaccine, DNA vaccine, cancer cell vaccine, and viro-
immunotherapy. 
Inspired by the first cancer immunotherapy conducted by Dr. William Coley who 
successfully treated his patients with intratumoral injections of microbial materials in late 
1800s, we recently evaluated the therapeutic efficacy of intratumoral administration of 
an adenovirus expressing Flagrp170, Grp170, or flagellin (113). We demonstrated that 
Flagrp170 is much more potent than either Grp170 or flagellin alone in eliciting a robust 
antitumor response in models of melanoma, colorectal, and prostate cancer. This 
therapeutic activity is dependent upon BATF3+ DCs, CD8+ T-cells, and NK cells as well 
as Gm-CSF, IL-12, and IFN-. Furthermore, this local treatment generates a systemic 
immune response capable of eradicating distant metastases (114, 115).  Given the 
presence of abundant TAA/TSAs present in the tumor sites, this Flagrp170-based in-
situ vaccination may be used to generate CTLs directed against the entire antigenic 
repertoire within the tumors. Since the ER retention KDEL motif has been removed from 
native Grp170, this allows for constitutive secretion of Hsp-TAA/TSA complexes from 
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infected cancer cells. Hsp-TAA/TSA complexes targeting APCs with the NK-B-
stimulating ‘danger’ signal carried by the chimeric Flagrp170 molecule will help optimize 
antigen cross-presentation and T-cell activation (115). A recent study published from 
our lab showed the mechanistic importance of the Nod-like-receptor CARD domain-
containing protein 4 (NLRC4), which functions as the intracelluar cytosolic pathogen 
senseing pathway for flagllin. In this publication we discovered that NLRC4 was more 
critical than TLR5 for the immune protection generated by Flagrp170, and that Gm-CSF 
produced by CD8 T-cells after Flagrp170 was indespensable in generating antitumor 
immunity. We hypothesis that since Flagrp170 is delivered virally, the cytosolic pattern 
recogniation receptor NLRC4 would likely be the target of immune activation as 
opposed to the membrane expressed TLR5 (116).  Although studies are still ongoing to 
better understand the molecular and cellular alterations within the tumor 
microenvironment following administration of this novel agent, our results strongly 
support the use of this next-generation Hsp molecule for improved vaccine development 
as well as for reprograming the tumor immune compartment to covert immunologically 
‘cold’ tumors into ‘hot’ ones. Furthermore, future studies using this platform will assess 
the feasibility of combining this agent with other conventional treatment modalities for 
improved therapeutic outcomes. 
Another recently created Hsp fusion molecule involved the modification of M. 
tuberculosis derived Hsp70 fused to a single chain variable fragment (scFv) antibody 
specific for mesothelin, an antigen expressed primarily in mesothelioma and ovarian 
cancer. This fusion protein, called scFvMTBHsp70, takes advantage of the inherent 
immunogenicity and peptide-chaperoning capacity of the M. tuberculosis-derived 
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Hsp70, allowing its delivery to the tumor microenvironment with the mesothelin-specific 
antibody. scFvMTBHsp70 has been shown to increase survival in ascites models of 
mesothelioma and ovarian cancer in a CD8+ dependent manner (117, 118). However, it 
remains to be determined whether the strong immunogenicity of microbial Hsp70 results 
in immune side effects in patients. 
 
RT and Immune Activation 
 
Whether the intent is curative or palliative, most cancer patients with solid tumors will 
undergo some form of RT during their course of treatment. The bulk of irradiated cancer 
cells die due to mitotic crisis caused by continued cell cycling in the presence of DNA 
double strand breaks. These breaks are caused by either direct attack by high-energy 
photons, or by reactive oxygen and nitrogen species generated as a consequence of 
ionization events (12). Despite the well-recognized cytotoxic and cytostatic effect on 
cancerous cells, it is becoming increasingly appreciated that the durable control of 
tumor by RT may involve the function of the host immune system (119, 120).  In very 
rare and sporadic reports, local RT results in regression of distant lesions or metastases 
outside of the scope of the field of radiation. This phenomenon, termed the ‘abscopal’ 
effect, is believed to be attributed to the systemic antitumor immunity activated by RT 
(12, 121). The mechanisms underlying RT-induced antitumor immune responses are 
complex and most likely involve active interplays between irradiated cancer cells and 
the tumor immune compartment. 
Multiple investigations have mostly attributed to the immunostimulatory effect of 
RT to an altered repertoire of TAAs available in the tumor microenvironment and 
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activation of tumor-infiltrating innate or adaptive immune cells. Radiation-induced 
exposure of antigenic peptides have been identified as a possible mechanism 
underlying RT-elicited antitumor immune response (15). Additionally, RT can trigger the 
‘danger’ signals within the tumor microenvironment, such as immunostimulatory 
cytokines, to potentiate cross-presentation of TAAs by activating DCs (122). Recently, 
RT has been shown to induce the production of type I IFNs through activation of 
intracellular DNA sensors, i.e., the cGAMP synthase-the cytosolic DNA-sensing 
stimulator of interferon genes (STING)-dependent pathway (123, 124). The STING 
pathway plays an essential role for CD8+-mediated antitumor responses (17). Upon 
binding to damaged self or foreign dsDNA, the pattern recognition receptor the cGAMP 
synthase catalyzes the production of cyclic GMP-AMP which then binds to the adaptor 
protein STING. STING translocates to the perinuclear space, binds to TBK1 and IRF3, 
leading to their phosphorylation and the subsequent production of IFN-β (125, 126). 
This type I IFN signaling is critical for the maturation and recruitment of CD103+BATF3+ 
DCs necessary for development of antitumor immunity (123, 127-133).  This response 
can also occur spontaneously in tumors that exhibit chromosomal instability, and pre-
existing activation of this pathway has been linked to patient responses to ICBs, 
providing further context for the rational combination of RT and immunotherapy (134). In 
addition to DC activation and T-cell priming, RT can also remodel the tumor vasculature 
to facilitate lymphocyte extravasation and recruitment via upregulation of vascular cell 
adhesion molecule-1 and chemokine CXCL16 (135-137).  
Although immunostimulatory effects of RT have been well documented, they are 
for the most part not sufficient to engage an effective antitumor immune response to 
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eradicate poorly immunogenic cancers. This may be caused by an immunosuppressive 
tumor milieu dominated by regulatory T-cells, myeloid-derived suppressor cells 
(MDSCs), and M2-polarized macrophages (10, 18, 138, 139). In addition, RT itself also 
elicits immunosuppressive factors that can dampen the effector functions of immune 
cells. Activation of TGF-β by RT has been shown to impair CTL function, and RT-
induced expression of chemokine stromal-derived factor-1 can recruit tumor-promoting 
and immunosuppressive myeloid cells (140-142). These immunoregulatory events may 
explain why the ‘abscopal’ effect of local RT remains extremely rare in the clinic. 
Nonetheless, strategic targeting of the major steps of the cancer-immune cycle may be 
exploited to augment systemic antitumor immunity in the setting of RT to amplify or 
reproducibly generate an abscopal response (21). 
 
Immune Targeting of Hsp for Enhanced RT 
 
Immunogenic cancer cell death (ICD) has been proposed to be a major mechanism 
involved in RT-induced antitumor immunity (143). ICD is often associated with surface 
expression or secretion of ‘immunogenic signals’ that fall in the category of DAMPs. RT 
has been shown to trigger translocation of the ER-resident chaperone calreticulin to the 
cancer cell-surface, which serves as an ‘eat me’ signal and enhances the 
immunogenicity of cancer cells (144, 145). DAMPs also allow efficient communication of 
the ‘antigenic pattern’ of dying cancer cells to the host immune cells and thereby 
eliciting potent antitumor immunity. Indeed, induction of an ER stress response, 
characterized by marked elevation of ER-resident chaperones (e.g., Grp94/Gp96, 
Grp170), has been identified as one of common features of ICD. Considering that 
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radiation exposure can induce the expression and release of Hsp that can serve as 
DAMPs as well as the cargo of TAAs, it is conceivable that these extracellular Hsp 
participate in the adaptive immune response by promoting antigen cross-presentation 
and T-cell priming (146).  However, to what extent these Hsp can help with antitumor 
immunity during RT has not been thoroughly explored. 
Several studies from our lab have shown that genetically engineering cancer 
cells to either overexpress or secrete the large Hsp (i.e., Hsp110, Grp170) dramatically 
increases tumor immunogenicity. Immunization of mice with these irradiated cancer 
cells provided preventative and therapeutic anticancer effects in multiple tumor models 
(78, 147, 148). The improvement of antitumor efficacy by ectopic expression of secreted 
Hsp appears to depend on CD8+ T-cells and NK cells. In addition, this strategy 
effectively expanded T-cell diversity for TAAs antigens, suggesting that passively 
released Hsp may be insufficiently immunogenic to drive a CTL response.  Thus, active 
Hsp-targeting approaches aimed at increased DAMP signals as well as processing and 
presentation of TAAs could be an effective avenue to expanding the T-cell repertoire 
during RT (147).  
Exosomes are 80-200 nm vesicles constitutively produced by all mammalian cell 
types. They are formed by inward budding of specialized endosomal compartments 
called multivesicular bodies and known to mediate cellular communications (149, 150). 
Similar to Hsp, exosome production can be enhanced during states of cell stress (151). 
Although it is unclear whether these proteins reside in the lumen or are associated with 
the exosomal membrane, Hsp such as Hsp70 and HSC70 are consistently detected in 
exosomes, and have served as reliable exosomal markers since their original discovery 
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(152). These exosomes also contain TAAs and can be taken up preferentially by splenic 
DCs (153). However, the immunoregulatory role of these Hsp within the tumor-derived 
exosomes is unclear. A recent study showed that exosomal membrane bound Hsp72 
suppressed antitumor immunity by stimulating signal transducer and activator of 
transcription 3-dependent immunosuppressive activity of MDSCs (73). However, it has 
also been reported that tumor-derived exosome vaccines generated potent antitumor 
immunity, which can be further enhanced when exosomes were prepared from cancer 
cells that experience heat shock or other cellular stresses (154). Indeed, our previous 
work demonstrated that Hsp110 isolated from thermally stressed cancer cells was more 
immunogenic in stimulating an antitumor immune response than those from untreated 
cells, suggesting that heat shock may alter Hsp-carried antigenic profiles and impacts 
on Hsp-induced antitumor immunity (44). 
Upon exposure to radiation, cancer cells undergo enhanced secretion of 
exosomes in a p53 dependent manner (151, 155, 156). In addition to Hsp and TAAs, 
exosomes derived from cancer cells exposed to hypofractionated radiation are capable 
of transferring STING stimulatory dsDNA to DCs, resulting in activation of type I IFN 
response. Mice vaccinated with the exosomes from irradiated tumor cells were shown to 
induce a potent antitumor immune response (153). Intriguingly, Grp170 not only bind to 
client proteins or polypeptides, but also can chaperone DNA substrate, such as 
microbial CpG oligodeoxynucleotides. Forming a complex of GRP170 and CpG 
oligodeoxynucleotides can significantly enhance activation of TLR9 signaling (157). It is 
of interest to examine Hsp-associated with tumor-derived exosomes and their 
immunoregulatory activity that may be altered by radiation-induced genotoxic stress as 
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well as potential Hsp interaction with dsDNA. Considering the ability of RT to enhance 
expression of unique TAAs for incorporation into exosomes, the study of the 
immunogenicity of tumor-derived exosomes as well as exosomal Hsp in the setting of 
RT may produce novel tools to help integrate RT and Hsp-targeting immunotherapies 
(15, 153, 158).  
Membrane bound Hsp70 induced by RT may serve as tumor-specific targets for 
NK cells, sensitizing irradiated cancer cells to ICD (146). In their unstressed state, 
mammalian cells present non-classical HLA-E molecules with bound HLA-A, HLA-B, 
and HLA-C leader peptides on their surface. They bind to the CD94/NKG2A inhibitory 
receptor complex and inhibit the activation of NK cells. In response to RT or 
chemotherapy, Hsp70 in some cancer cells will translocate to the outer leaflet of their 
plasma membranes to interact with phosphatidylserine (159). A Hsp70-derived signal 
peptides compete with the leader peptides for binding to HLA-E, thereby disrupting 
CD94/NKG2A activity and promoting cytolytic function of NK cells (146). Treatment of 
membrane Hsp70+ non-small cell lung carcinoma patients with autologous NK cells ex 
vivo activated with Hsp70-derived signal peptide and IL-2 is currently being tested in 
clinic (111). 
Given the development of next-generation Hsp-based immunotherapeutic agents 
(i.e., Flagrp170) that are engineered to carry a defined microbial signal, administration 
of such a hybrid molecule of PAMP and DAMP to the tumor sites during RT could 
greatly improve the ICD. The feasibility and therapeutic efficacy of intratumorally 
delivering Hsp as well as this chimeric Hsp has been experimentally established in 
mouse cancer models (115, 160).  The uniquely combined actions of Flagrp170 in 
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facilitating antigen cross-presentation while concurrently delivering a microbial 
immunostimulatory signal for optimized antigenicity and co-stimulation should strongly 
provoke ICD upon irradiation. Our previous work showed that CD8+BATF3+ DCs were 
required for the therapeutic efficacy of Flagrp170-based in situ vaccination (115). 
Several lines of evidence suggest that radiation treatment may be harnessed to expand 
or recruit CD103+BATF3+ DCs to the tumor sites to further drive ICD together with Hsp-
based immune reprograming of the tumor (17, 161, 162).  Studies are ongoing to 
evaluate this novel agent in the context of RT for its potency to induce an abscopal 
effect via systemic mobilization of innate and adaptive immune arms.  
As a major Hsp-binding receptor, SRA was shown to negatively regulate the 
immunogenicity of mouse cancer cells treated by ionizing radiation, supporting a 
scientific rationale for combining RT with SRA-blocking therapy (91). Our subsequent 
study demonstrated that intratumoral administration of SRA-silenced DCs enhanced the 
treatment outcome of RT against mouse prostate cancer and metastases, which was 
mediated by IFN-γ-producing CTLs (163).  Together with the data on the impact of SRA 
on Hsp-based cancer vaccination, it is evident that SRA plays an important role for 
determining the immunogenicity of both Hsp-based vaccines and dying cancer cells 
during RT. Therefore, pharmacologic, genetic, or biological approaches to targeting 
SRA should be considered when combining RT and Hsp-based immunotherapy. 
Together, these findings suggest that their combination could strengthen the ICD 
signals, deliver target antigens, and overcome the immune dysfunction in the tumor 
microenvironment following RT. 
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Over the past few years immune checkpoint inhibitors targeting cytotoxic 
lymphocyte antigen-4 (CTLA-4), programmed cell death protein 1 (PD-1) or its ligands 
PD-L1/2 have changed the treatment paradigms in medical oncology. Several 
antibodies (e.g., ipilimumab, nivolumab, pembrolizumab) targeting these T-cell 
suppressive immune checkpoint pathways have been approved by the US FDA and 
have been shown to improve overall survival for patients with certain 
metastatic/recurrent cancers (164, 165). Given the immunoregulatory effects of RT 
through diverse mechanisms, a logical next step is to combine RT and ICB therapy to 
reverse cancer-mediated immunosuppression and potentiate durability of an antitumor 
immune response. Currently, there are hundreds of phase I-III clinical trials testing this 
combinatorial therapy in patients with different malignancies or at different stages. While 
these studies are expected to provide important insights regarding feasibility and 
benefits of combined RT and ICB in the clinic setting, the clinical trials should be 
designed to ensure combination treatments are supported by scientific rationales and 
experimental evidence (10, 139).  In a recently completed phase III trial that evaluated 
RT combined with anti-CTLA-4 therapy in metastatic castration-resistant prostate 
cancer, its primary endpoint was not met, indicating that additional approaches must be 
considered to improve the overall treatment outcome (166). Indeed, collective pre-
clinical and clinical evidence suggests that tumors responding to immune checkpoint 
inhibitors tend to exhibit a “T-cell inflamed” phenotype prior to the initiation of treatment 
(167-170). These reports highlight the potential for Hsp-based cancer vaccination 
platforms to expand pre-existing antitumor T-cell repertoires, and reprogram the 
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immune landscape of immunologically ‘cold’ tumors, to improve clinical response rates 
of ICB therapy.  
 
Head and Neck Squamous Cell Carcinoma (HNSCC) Application 
 
Head and neck cancer (HNSCC) cases are projected to increase by 30% over the next 
decade globally, and it is the sixth most common cancer diagnosis in the world (171). 
While overall survival remains high particularly in human papilloma virus (HPV) positive 
HNSCC cases, the overall survival rate has remained stagnant at around 60% over the 
past decade (172). According to the surveillance epidemiology and end results (SEER), 
overall survival is around 60%, however, more than half of patients diagnosed yearly 
present with distant or metastatic disease, which significantly drops the five-year 
survival rate. Additionally, survivors of this disease have the second highest rate of 
suicide amongst all cancer patients (63.4 cases per 100,000), because of the poor 
quality of life, impart of the aggressive treatment regimens that confer a high survival 
rate (173). Biomarkers associated with improved outcomes like the expression of E6 
and E7 oncoproteins seen in HPV+ HNSCC, are known to target p53 and the 
retinoblastoma associated protein (Rb) proteins for ubiquitination and degradation, 
respectively. These activities push cell cycle progression past the restriction point, 
which drives the creation of a malignant neoplasm. This HPV driven event is 
characterized by increased P16ink4a as a result of Rb degradation caused by the E7 
protein (174). The upregulation of P16ink4a seen via immunohistochemistry serves as a 
surrogate marker for the clinical diagnosis of HPV+ HNSCC, and is a known inhibitor of 




Treatment regiments for HNSCC are multimodal and include surgical intervention as the 
typical first line therapy. RT doses range from 62-72Gy delivered in 2-2.5Gy fractions 
five days a week, often in combination with cisplatin-based chemotherapy (177). The 
treatment regimen selection depends upon several factors. The cancer stage, known 
extent of metastasis, and the primary sites of origin dictate what treatment modality will 
yield the most clinical benefit for survival and quality of life. Typically, patients 
presenting with a localized primary tumor and no metastasis to the lymph nodes, 
receive a monotherapy of either surgery, or RT. This cohort of patients will benefit from 
cure rates of greater than 80% with monotherapy treatment (178). However, there are 
reports of cases where a small, yet invasive primary tumor producing nodular 
metastasis are more easily identified by elective neck dissection as opposed to RT 
(179). The selection for a surgical intervention occurs mostly in patients with 
malignancies in the oral cavity (171). Whereas, RT is typically used in deeper locations 
like the pharynx or larynx, which have shown an increased response rate with hypo-
fractionated doses as oppose to the conventional RT regimen (180, 181). In patients 
with aggressive invasive tumors, increased tumor burden, or perineural invasion, post-
surgical cisplatin chemotherapy and RT (chemo-radiation) offer significantly higher 
overall survival (OS), and lower tumor re-occurrence risks (171, 182, 183). However, 
the late effects of radiation therapy are more prevalent in patients who receive post-
surgical chemo-radiation regiments, significantly lowering the quality of life after 
treatment (184). Therefore, new treatment modalities that could lower the curative 
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doses of RT or cisplatin therapy required will aid in reducing the late effects patients 
experience after treatment.  
 
Recently, ICB therapy has been approved as first line therapy in patients with advanced 
metastatic disease, or recurrent disease. Patients are candidates if they have 
undergone cisplatin therapy within six months, exhibit tumor microsatellite instability, or 
if they have a PDL1 expression in the tumor. PDL1 tumor expression is measured via 
immunohistochemistry, and the composite positive score (CPS) serves as the 
quantitative clinical scale (ranging from 0-100) used for decision making regarding the 
level of PDL1 expression (171). Contraindications for ICB include autoimmune 
conditions or having received cisplatin therapy more than six months prior. Patients with 
a CPS<1 are recommended a chemo-radiation regimen or clinical trials. Asymptomatic 
patients with CPS>20 and low tumor burden are recommended ICB as a monotherapy 
given the high PDL1 expression, or a clinical trial. However, patients with CPS range of 
2-19 are recommended dual ICB and cisplatin therapy, or a clinical trial given their 
moderate PDL1 expression. These clinical recommendations were founded upon the 
KEYNOTE-048 clinical trial comparing Pembrolizumab (an antibody inhibiting PD-1) 
verses combination of chemotherapy and cetuximab, or Pembrolizumab alone (185).  
Comparatively across all patients (mixed CPS scores), Pembrolizumab as a 
monotherapy compared to Pembrolizumab plus chemotherapy was inferior in terms of 
OS (11.6 months vs. 13 months). However, in patients with CPS scores ≥20 or ≥1, 
Pembrolizumab monotherapy was superior to chemotherapy plus cetuximab (OS 14.9 
months vs. 12.3 months respectively) due to the increased tumor PDL1 expression 
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conferring a likely response rate to the therapy. Furthermore, clinicians favor the use of 
the combination of ICB (PD-1 inhibitors approved in HNSCC) and chemotherapy given 
the increase survival rates with the dual implementation (171, 176, 178). This decision 
is even more likely in patients with larger or bulky tumors given chemotherapy efficacy 
as a de-bulking agent aids in improvement of immunotherapy generally. Alternatively, 
patients with lower tumor burden are spared additional rounds of chemotherapy and are 
treated with mono-ICB.  
 
Next Generation Hsps Cancer Vaccines may Improve Clinical Response Rates 
 
The constitutive expression of Hsp as molecular chaperones and their upregulation as 
part of a stress response is crucial for maintaining cellular functions. The inherent 
chaperoning property of these Hsp has provided a molecular basis for tumor-derived 
Hsp preparations being used as cancer vaccines to elicit an antitumor immune 
response against the tumor antigenic fingerprint carried by Hsp. This similar principle 
has also been utilized to reconstitute Hsp-TAA complexes for targeted vaccination or to 
genetically engineer cancer cells to produce Hsp-TAA complexes as cellular vaccines. 
Hsp provide an attractive platform for vaccine therapy given their superior ability to 
preferentially deliver TAAs to APCs for enhanced cross-presentation. The successful 
pre-clinical studies of different forms of Hsp-based immunotherapies have led to 
multiple phase I-II trials in patients with advanced malignancies. Although there were no 
significant toxicities as expected, the results from the clinical trials of Hsp-based cancer 
vaccination have been modest. While multiple reasons may be involved, it is evident 
that new strategies for improving Hsp-based immunotherapies are needed. Our recently 
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developed next-generation Hsp vaccine vehicle (i.e., Flagrp170) appears to be 
promising in potentiating antitumor immunity and more importantly in reprograming the 
immunosuppressive tumor microenvironment, allowing for enhanced T-cell infiltration 
and cytotoxic activity. RT is a conventional treatment modality that is widely used in the 
clinic to achieve local control of tumors in the irradiated area. In addition to the direct 
cytotoxic effect on cancer cells through DNA damage, RT can induce an immune-
mediated antitumor response, exemplified by limited clinical cases of abscopal effect. 
Given the distinct mechanisms of action, RT and immunotherapy hold the potential for 
synergistic cancer management, therefore, many efforts have been made to pursue 
rationally combined RT and immunotherapy. Encouraging preclinical data have 
stimulated translation of this combinatorial modality. However, clinical data from trials 
that combined RT with other immune modulating agents, e.g., ICB, vaccines, have only 
shown a modest response. Due to the unique aspects of Hsp-mediated 
immunomodulation, Hsp-based vaccination may strengthen the ICD during RT to 
achieve reliable induction of abscopal effect for eradicating both irradiated and distant 
metastases. Hsp-directed therapy can help provide the T-cell diversity that is critically 
needed to target the heterogeneity often seen in human solid cancers. Particularly, 
reshaping the tumor immune compartment using the next-generation Hsp-based 
immunotherapeutic agent holds a promise in improving the immunogenicity of cancer 
cell death during RT for personalized vaccination and augmenting systemic antitumor 
immunity necessary for an abscopal therapeutic effect. However, the key to furthering 
these multimodality treatment strategies will be to develop a better understanding of the 
immunologic and genetic mechanisms that underpin the efficacy of different therapies. 
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This will aid in the development of relevant predictive biomarkers that may help stratify 
the patient populations that can benefit from this integrated approach. Questions also 
remain regarding radiation parameters such as the timing, dose, and fractionating 
schedule as well as the preferable disease setting to test combination strategies. It 
should also be noted that RT itself can bring multiple immune-limiting factors, such as 
immunosuppressive cytokines and the recruitment of MDSCs, alternatively activated 
macrophages, and phenotypically tolerogenic APCs, which must be addressed before a 
lasting tumor protective immunity can be achieved. Moreover, immune activation by 
active Hsp-targeted vaccination often triggers immune checkpoint pathways (e.g., PD-
1/PD-L1) that will counteract the activity of immune effector cells (e.g., CTLs). 
Therefore, integration of immune checkpoint inhibitors into the treatment protocol not 
only will reinvigorate exhausting T-cells in the tumor microenvironment, but also can 
further leverage on vaccination-expanded T-cell repertoire to maximize the full potential 
of the combination RT-Hsp therapy regimens in the clinic.  
 
Copyright Disclaimer 
Portions of this introduction were previously published:  
Patrick A. Paez*, Gene C. Clark*, Chunqing Guo, Ross Mikkelsen, John R. Subjeck, 
Elizabeth A. Repasky and Xiang-Yang Wang. “Role of Heat Shock Proteins in 
Antitumor Immunity: A Perspective on the Abscopal Effect of Radiation Therapy 
Heat Shock Proteins.” Springer Nature Heat Shock Proteins: Chapter 12 Volume 
(Accepted 2020, pending press) (Asterisk denotes co-first author) 
 
METHODS 
Animals and Murine Cell Lines 
 
Female C3H/HeN mice and C57BL/6 mice that were six to eight weeks of age were 
purchased from Jackson Laboratory (Bar Harbor, Main, USA). The murine head and 
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neck squamous cell carcinoma cell line SCC VII was a kind gift from Dr. Gal Shafirstein 
(Rosewell Park Comprehensive Cancer Center) and the MOC II cell line was a kind gift 
from Dr. Joing Li (Virginia Commonwealth University). The SCC VII cells were cultured 
in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS), 10mM 2-[4-
(2-Hydroxyethyl)-1-piperazinyl]ethanesulfonic acid (HEPES free acid), 2mM L-
glutamine, and 100U/mL penicillin, and 100µg/mL streptomycin antibiotics. SCC VII 
cells were transfected to express whole OVA-albumin protein using a pCDNA3.1 
plasmid containing OVA, with polyethyleneimine transfection as described by 
manufacturer (Sigma Aldrich, Darmstadt, Germany). The MOC II cells were cultured in 
Dulbecco’s Modified Eagle’s Medium F-12 supplemented with 10% FBS, 10 mM 
HEPES free acid, 2 mM L- glutamine, 100 U/ mL penicillin, and 100 µg/mL 
streptomycin. MOC II Luciferase/TD tomato expressing cells (MOC II Luc/Tdt) were 
generated by lentivirus transfection and gentamicin selection from pcDNA3.1 plasmid 
construct, a kind gift from Dr. Ross Mikkelsen.  Cell lines were also routinely tested for 
the presence of mycoplasma using a PCR-based method of detection (ATCC, 
Manassas, Virginia, USA).  
Generation of Replication Deficient Adenovirus 
 
Replication deficient adenovirus was produced using 293A cells. The construct carried 
human or mouse Grp170 with the ATP binding domain truncated, KDEL ER retention 
sequence motif removed, and fused to the NFB activating domain from flagellin. 
Flexible linkers were used to attach the NFB activating domain to Grp170 and a 
signaling peptide aiding in secretion of the chimeric heat shock protein. Recombinant 
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adenovirus was packaged and then purified using AdenoPack Maxi spin columns 
(Sartorius Stedim Biotech, Bohemia, New York, USA) (115, 116).  
In vivo Tumor and Immune Neutralization Studies 
 
SCC VII cells were cultured and 2 x 105 cells were implanted subcutaneously in the 
flanks of female C3H/HeN female mice 6-8 weeks of age. In abscopal effect 
experiments, bilateral tumors were implanted and in single tumor models, only the right 
flank was inoculated with SCC VII tumor cells. The right flank received 2 x 105 
cells/injection and the left flank received 1 x 105 cells/injection if the metastatic model 
was being used to demonstrate abscopal responses. Immune cell depletion 
experiments were conducted by injecting animals intraperitoneally with monoclonal 
antibodies (200µg) targeting CD4 or CD8 T-cells three days prior the beginning of the 
experiment. Depletion antibody clones for CD8 T-cells (clone 2.43), CD4 T-cells (clone 
Gk1.5), and IgG control was purchased from BioXcell (West Lebanon, New Hampshire, 
USA). Tumors were measured by tumor volume, as defined by V = (shortest dimeter2 x 
longest diameter)/2 producing tumor volume (mm3). Animals were euthanized once 
tumors reached 2048mm3 in diameter as approved by the VCU Institutional Animal 
Care and Use Committee (IACUC). 
In vivo Stereotactic Radiation 
 
Animals were anesthetized using isoflurane, imaged then irradiated using the Small 
Animal Radiation Research Platform (SARRP) Xstrahl model (Suwanee, Georgia, 
USA). A computerized tomography (CT) image was taken first to create an isocenter 
dose of the animal’s tumor, dosimetry and planning was completed using MuriPlan from 
SARRP as previously published (186). Stereotactic CT guided radiation was then 
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delivered using a 10mm collimator, at either 2.5Gy/day or 10Gy/day for three 
consecutive days depending upon the experimental model used in the experiment.  
Flow Cytometry and ELISA 
 
Tumors were digested using collagenase D (1mg/mL) and DNase I (40µg/mL) at 37°C 
using the gentleMACS tumor dissociation machine (Miltenyi Biotec, Gladbach, 
Germany). Tumor infiltrating leukocytes where then enriched using Percoll at a 40% and 
70% gradient and centrifuged as recommended by the manufacturer (Sigma Aldrich, 
USA). TILs or splenocytes for intracellular staining were stimulated in complete RPMI 
medium containing phorbol 12’-myristat-13’acetate (PMA) at 10nM with ionomycin 
(0.5µM) for three hours and then blockage of the golgi with brefeldin A (BFA) 5µg/mL for 
two hours. Receptor staining occurred with live/dead zombie dye as manufacturer 
recommendations, then CD16/32 block with 2.4G2 at 4°C for 15 minutes, followed by 
the addition of receptor antibodies for staining in the dark for a duration of 30 minutes. 
Cells were washed three times with PBS, and fixed with 4% paraformaldehyde for 15 
minutes at 4°C in the dark. Cells were then prepared for permeabilization for 30 minutes 
followed by the addition of intracellular antibody targets, plus 2.4G2 for an additional 30 
minutes of staining. Cells were then washed three times with permeabilization buffer 
and then fixed with 4% PFA for 15 minutes before resuspending with FACS buffer. 
Flow cytometry antibodies used were the following: FITC granzyme B (clone Gb11), 
FITC CD86 (GL-1), PE IFN-γ (XMG1.2), PE GM CSF (MP1-22E9), PE CD80 (16-10A1), 
PE Cy7 CD44 (BJ18), APC CD45 (30-F11), BV421 TCR-β (H57-597), zombie dye aqua 
live dead stain, BV711 CD62L (MEL-14), BV711 CD11c (N418), APC-FIRE750 CD4 
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(GK1.1) (Biolegend, San Diego, California, USA) BUV395 CD8, BUV737 CD11b 
(M1/70) (BD Bio sciences San Jose, California, USA). 
Quantitative PCR Analysis (qPCR) 
 
Real-time quantitative PCR was performed as previously described (115). In these 
experiments RNA was extracted using TRIzol reagent (Thermofisher Scientific). 
Reveres transcription and qPCR were performed using carboxylfluorescein FAM-
labeled probed purchased from Thermofisher Scientific. Immune genes were analyzed 
and normalized to β-actin and then experimental control groups using the standard 2-
ΔΔCt calculation formula. 
Statistical Analysis 
 
All data in this thesis was analyzed using Graphpad Prism 9 and were expressed in 
mean SD or SEM values. Statistical significance between three or more groups was 
determined via One-way ANOVA, statistical significance between two groups was 
determined via a student’s t-test, and statistical significance between tumor growth 
curves or survival was determined via Two-way repeated measures ANOVA or Log-
Rank test respectively. Asterisks denote statistical significance of: * P≤ 0.05, ** P≤0.01, 







Ad. Flagrp170 Intratumoral Injections Potentiate RT, Synergizing to Promote 
Antitumor Immunity. 
 
Using the HNSCC carcinoma model SCC VII with syngeneic C3H/HeN mice, we studied 
the ability of Flagrp170 to potentiate RT in vivo. The prominently used SCC VII model 
tumor has been previously described to have a genetic profile akin to the human 
disease state of HPV negative HNSCC (187). SCC VII cells transfected to express 
OVA-albumin (SCC VII-OVA) were implanted subcutaneously (2x105cells/injection) and 
then treated once tumors reached 8-9mm in diameter. Animals remained untreated or 
were either treated with empty adenoviral vector (null), or adenoviral Flagrp170 
intratumorally at a dose of 2 x 108 PFU/dose, q.a.d., for five doses. RT was delivered at 
2.5Gy dose stereotactically for three fractions in succession using a Small Animal 
Radiation Research Platform (SARRP). Flagrp170 combination with RT significantly 
reduced tumor volumes as compared to combination null, and the no treatment (control) 
groups (Figure 1A). Upon analysis of tumor infiltrating leukocytes, it was found that 
Flagrp170 combination treated tumors had a significant increase of IFN-γ+ CD8+ T-cells, 
and CD8+ effector memory (Em) T-cells (Figure 1b). Similarly, CD4+ T-cells displayed 
an increase of IFN-γ+, TNF-α+, and Tem phenotype at the tumor site (Figure 1C). As a 
metric of systemic immunity, splenocytes from tumor bearing mice were collected ex 
vivo and stimulated with whole cell lysates (WCL) or OVA protein for 96-hours. The 
combination of Flagrp170 treatment produced significantly higher levels of IFN- γ when 
splenocytes were activated with both WCL or OVA protein as determined by ELISA 
(Figure 1D). Gene analysis at the tumor site further supported a statistically significant 
increase of IFN-γ and a trend towards significance in granzyme B levels in Flagrp170 
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and RT combination group (Figure 1F). Furthermore, a dose response of RT delivered 
in three fractions using 7.5Gy, 15Gy, and 30Gy with either null or Flagrp170 treatment, 
displayed an improved curative therapeutic index of RT. We achieved tumor control and 
improved survival with the lowest dose of RT with the addition of Flagrp170 as 
compared to RT and null treatment (Figure 1E).  
 
Flagrp170 Promotes Efficient Antigen Presentation Cell Priming and Activation in 
Draining Lymph Nodes, 16-hours post-Vaccination. 
 
SCC VII cells were cultured, irradiated, and infected with either null virus or Flagrp170 
at a multiplication of infection (MOI) of 1:300 in vitro and used to vaccinate C3H/HeN 
animals subcutaneously. Draining lymph nodes (DLNs) were then harvested after 16-
hours post vaccination and analyzed via flow cytometry (Figure 2A). Upon analysis, 
CD11b+, CD11c+ dendritic cells in the animals’ DLNs, vaccinated with irradiated and 
Flagrp170 infected SCC VII tumor cells, displayed a significant CD80, and CD86 
receptor increases, as compared to null virus infected SCC VII group (Figure 2B). 
Within the subsets of dendritic cells, CD8+ dendritic cells (Figure 2C) and CD103+ 
dendritic cells (Figure 2D) expressed a higher frequency and mean fluorescence 
intensity (MFI) of both CD40 and MHC II after vaccination with Flagrp170 irradiated cells 
at the DLN site. These data support the immunostimulatory function of Flagrp170 at the 
level of the antigen presenting cells whose sentinel function is to initiate an adaptive 




Radiation Therapy Combination Conferred Protection through Flagrp170, 
Improves Survival and Tumor Re-occurrence Risk. 
 
C3H/HeN female mice were inoculated with SCC VII tumor cells subcutaneously on 
day-0. Once tumors reached 5-6mm of diameter in size, three 10Gy fractions of RT 
were delivered stereotactically in three days. Concomitantly, intratumoral treatment with 
either null or Flagrp170 was also delivered q.a.d. for five doses, and the animals’ tumor 
volumes and survival were measured and recorded. Animals that remained tumor free 
for two months were subsequently re-challenged on the contralateral site with SCC VII 
cells and monitored for tumor reoccurrence as depicted in the experimental schematic 
in (Figure 3A). Flagrp170 combination RT treatment resulted in 86.67% survival, as 
compared to the 33.33% survival rate of the combination null and RT treatment. This 
survival difference was statistically significant via a Log-rank test (p <0.001) (Figure 
3B). Animals that remained tumor free for two months, were re-challenged with SCC VII 
tumors on the contralateral flank and then monitored for tumor re-occurrence. A 
representative image of animals re-challenged with SCC VII tumors on the contralateral 
side (Figure 3C) shows the conferred immunological protection from Flagrp170. There 
was with 23% (3/13) tumor reoccurrence in the Flagrp170 combination group, as 
compared to 100% (5/5) tumor reoccurrence in null combination group (RR=.18; p= 
0.003; CI 95%) as displayed in the table and graphs in (Figure 3D). Splenocytes from 
re-challenged animals were stimulate with whole cell lysates from SCC VII tumor cells 
for 96-hours and then analyzed via flow cytometry for intra-cellular cytokine production. 
The ex vivo splenocyte assay showed increased CD8+ T-cell activation and expression 
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of granulocyte-macrophage colony stimulating factor (Gm-CSF) and IFN-γ as seen in 
the representative plots in (Figure 3E) and graphs (Figure 3F). 
 
Mechanisms of Tumor Rejection in the SCC VII Model post-Flagrp170 Treatment 
 
Flagrp170 and RT combination treated animals were treated with the same treatment 
regimen schedule described in (Figure 3). Two weeks after ablation of the primary 
tumor animals were treated with targeted immune depleting antibodies including CD4+ 
T-cells, CD8+ T-cells, and the IgG control antibodies. Three days after the beginning of 
the selective immune depletion, animals were re-challenged with SCC VII cells on the 
contralateral side and monitored for tumor re-occurrence. Animals treated with IgG 
antibodies served as the control for the experiment and did not develop tumors as 
expected. Interestingly, animals depleted of CD8+ T-cells did not develop tumors, 
indicating that CD8+ T-cells, which have canonically been associated with antitumor 
immunological memory were dispensable for protection. Three out of the five animals 
depleted of CD4+ T-cells developed tumors indicating that in this model, they played a 
causal role in immunological protection and memory response Figure 4. 
 
Potentiation of the Abscopal Effect with Flagrp170 Treatment and Radiation 
Therapy Provides Improved Antitumor Immunity at Distant and Untreated Sites. 
 
C3H/HeN mice had bilateral SCC VII-OVA tumors implanted on the right and left flank 
on day 0. Treatment of the right tumor began once it reached 5-6mm in diameter with 
30Gy of RT delivered stereotactically in three fractions, and either null or Flagrp170 
intratumoral treatments for five doses q.a.d. (Figure 5A). The contralateral tumor on the 
left side of the animals remained untreated from the stereotactic RT or intratumoral 
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injections serving as a pseudo-distant and metastatic site for this portion of the study. 
Primary treated tumors on the right side achieved a complete response from animals in 
both RT groups by day 18, as compared to the control group. The Flagrp170 RT 
combination animals’ contralateral and untreated tumors grew at a significantly reduced 
volume when compared to the null RT combination group (Figure 5B). Upon immune 
analysis of tumor infiltrating leukocytes in the contralateral tumor, an increase of CD4+ 
and CD8+ T-cell frequency was found within the distant and untreated tumor. 
Furthermore, both CD4+ and CD8+ T-cells had increased IFN-γ production in the 
Flagrp170 and RT combination group as compared to the null and RT combination 
(Figure 5C). Myeloid cells in the contralateral site were also examined via flow 
cytometry. Flagrp170 and RT combination reprogramed the tumor microenvironment by 
decreasing monocytic myeloid derived suppressor (m-MDSC) cell frequency and 
increasing IL-12p40+ expressing dendritic cells in the contralateral and untreated tumor 
site (Figure 5D). Splenocytes from tumor bearing animals were stimulated ex vivo with 
whole tumor cell lysates for 96-hours and analyzed via flow cytometry. Flagrp170 and 
RT combination therapy displayed increased levels of IFN-γ from CD8+ T-cells as seen 
in both the representative flow cytometry plots and graphs (Figure 5E). Whole tumor 
tissue was collected ex vivo for RNA extraction and then cDNA was prepared and 
analyzed for Th1 genes via qPCR. Flagrp170 and RT combination produced higher 
relative expression of Tbet, granzyme B, and IFN-γ as compared to null and RT 





MOC II HNSCC metastatic model controlled via Flagrp170 mediated abscopal 
effect 
 
In Figure 6, we used another well-known HNSCC animal model called MOC II, which is 
syngeneic for C57BL/6 mice. MOC II as opposed to the MOC I cell line, exhibits a more 
aggressive and metastatic growth in vivo and is far less immunogenic as compared to 
MOC I, given its significantly lower expression of MHC I (188). Animals had MOC II 
tumors implanted subcutaneously and when the tumors reached a volume of 5-6 mm in 
diameter, the following treatments began: stereotactic RT, 7.5Gy in three fractions and 
intratumoral infusion therapy with either null of Flagrp170 (2x108 PFU/50µL) for five 
doses q.a.d. Animals were monitored for tumor volume and the combination therapy of 
RT and Flagrp170 provided better tumor control as compared to RT and null Figure 6A. 
Tissues were collected, RNA was extracted, cDNA was made and qPCR of target 
immune genes within the tumor were analyzed. In the MOC II tumors, increases of IFN-
γ, TNF-α, and IL-15 were found in the combination treatment of RT and Flagrp170 as 
compared to RT and null combination treatment group (Figure 6B). To further 
investigate this tumor models potential for control, we used a high fractionated dose of 
30Gy, which was delivered in three fractions at MOC II luc/Tdt tumors. These animals 
were then monitored for tumor growth via caliper measurement (Figure 6C), IVIS 
imaging for in vivo tumor burden monitoring (Figure 6D). 
 
Flagrp170s Control of the B16 Melanoma Lung Metastasis Model 
 
C57/BL/6 mice had a primary B16 tumor implanted subcutaneously and then three days 
later an intravenous injection of B16 tumor cells were delivered for the establishment of 
lung metastasis as previously described (115). RT groups showed efficacy in controlling 
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the primary tumor growth, however, combination RT and Flagrp170 verses RT and null 
trended towards significance (Figure 7A). Animals were sacrificed at day 21 and lungs 
were removed ex vivo for imaging, and upon gross observation, groups that received 
RT of the primary tumor appeared to experience more lung metastatic growth (Figure 
7B). Further analysis of the lung tissue was conducted by blinded counting of gross 
observational nodules, and a clonogenic assay was conducted of single cell 
suspensions created from the lung tissue (Figure 7C). The blinding count numbers 
trended with an increase of counts or increased metastasis with groups that received 
RT, including the RT and Flagrp170 combination groups. However, the clonogenic 
assay showed that that viable lung tumor cells seeded in 6-well plates to be a sign of 
lower tumor burden. This could be explained as a rapid tumor growth in vivo generated 
by ectopic intravenous injection of live tumor cells honing to the lung, and our 
therapeutic agent requiring the 5-7 days for immune activation. This delay in production 
of cytotoxic response still likely resulted in death-pathways being activated within the 
tumor cells and this event would not have been accounted for in gross blinding counting 
of nodules. Further analysis of the tissues will be required for a more holistic 
understanding of the immunological response conferred by Flagrp170 in this model. 
Upon analysis of the tumor infiltrating leukocytes, an increase of CD4 and CD8 T-cells 
expressing IFN-γ was detected via flow cytometry in the primary site from the Flagrp170 
treated groups (Figure 8A). Interestingly, CD4 T-cells made more IFN-γ in the primary 
site than the Flagrp170 mono therapy group as compared to the RT and Flagrp170 
combination treatment group. However, the trend reversed in the CD8 T-cell analysis, 
as the combination group produced marginally more IFN-γ than the mono therapy 
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group. Tumor tissues were also taken for analysis of qPCR immune related gene 
expression at the primary site (Figure 8B). Flagrp170 groups at the primary site 
produced more IFN-γ, granzyme B, IL-10, PD-1, and PDL2, while FoxP3 showed subtle 
trends with RT treatment groups. Interestingly, Flagrp170 monotherapy group did trend 
with IFN-γ, and granzyme B increases, as compared to RT and null treatment, but the 
combination of Flagrp170 and RT made significantly more only in IFN-γ. Inhibitory 
signals like IL-10, PD-1, and PDL2 were also more prevalent in the Flagrp170 treatment 
groups as compared to RT and null treatment. However, the combination of RT and 
Flagrp170 exacerbated all of these inhibitory signals at the tumor site significantly (IL-10 
trending, not statistically significant) while FoxP3 showed trending results as well. Upon 
flow cytometry immune analysis of the metastatic site (lung), CD4 T-cells appeared to 
promote greater IFN-γ expression in the Flagrp170 as compared to RT and null. 
Interestingly, CD4 T-cells in the lung expressed more IFN-γ in the Flagrp170 and RT 
combination group as compared to the monotherapy of Flagrp170. CD8 T-cells 
displayed modest increases of IFN-γ, when comparing RT and null verses Flagrp170 
monotherapy. The combination of Flagrp170 did produce almost 15% more IFN-γ in the 
CD8 T-cells of the lung as compared to RT and null treatment, however, deeper 
analysis of the functionality of these CD8 T-cells would need to be conducted to further 
support this claim (Figure 9A). In order to gain a further understanding of the immune 
modulation at the metastatic site, lung tissues were taken for qPCR analysis of immune 
related genes (Figure 9B). Immune activating genes like IFN-γ and granzyme B were 
increased in the lung with Flagrp170 treatment of the primary tumor, and more 
significantly with the combination treatment of RT and Flagrp170. IFN-β increases 
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trended with groups receiving RT at the primary site as compared to control and 
Flagrp170 monotherapy groups. Interestingly the addition of Flagrp170 to RT seemed to 
cause this IFN-β to trend down, possibly because of the multiple inhibitory signals 
occurring within the metastatic site. Several inhibitory signals like IL-10, PD-1, PDL1, 
PDL2, and FoxP3 were also analyzed at the metastatic site. Flagrp170 monotherapy 
had a trending increase of these aforementioned inhibitory signals however, the 
combination of RT and Flagrp170 significantly increased IL-10, PD-1, PDL1, PDL2, and 
FoxP3 at the metastatic site as compared to the monotherapy of Flagrp170. These data 
could explain why the blinded counts of the tumor trended to the conclusion of 
increased tumor burden. Conversely, the increased cytotoxic activity from Flagrp170 
and RT treatment groups seen via both flow cytometry and qPCR analysis could explain 
the significant viability differences from the clonogenic assay seen in (Figure 7C). 
These data could be an indication of limitations of ex vivo flow cytometry analysis, 
meaning that the immune suppression while the tissues were intact was lost through ex 
vivo activation of the single cell suspension of tumor infiltrating leukocytes. Furthermore, 
these data suggest that the B16 melanoma have cytokine sinks (i.e. “pockets of 
concentrated immune-suppressive cytokines within tissues”) created with the robust 
immune activation produced by Flagrp170 at the distant site (i.e. the lung) and that low 
dose cyclophosphamide or other cytokine sink depleting agents would likely benefit this 






The Double-edged Sword of RT 
 
Given that more than 50% of cancer patients will be treated with RT, and that abscopal 
effects are considered a clinically rare phenomenon, a comprehensive immunological 
understanding of how to increase the likelihood of a clinical abscopal effect is a 
landmark the field has yet to achieve. RT is delivered with a curative intent, most often 
seen in combination with chemotherapy, especially in inoperable locations for patients 
harboring metastatic disease. While there are positive effects in irradiating a primary 
tumor, the cell death mediated by mitotic catastrophe does not always confer a positive 
effect on metastatic tumors (189). The overwhelming body of evidence shows that 
suboptimum irradiation (i.e conventional fractionation) of a primary tumor, increases 
growth of metastatic lesions in several carcinoma settings, the earliest reports include 
HNSCC (190-196). The best rationale explaining the enhancement of metastatic growth 
has been seen in bladder and non-small cell lung cancer. In these clinical studies, upon 
the RT of primary tumors, an increase of circulating tumor cells (CTCs) in the blood 
were discovered, contributing to the increased metastatic burden (191). The proposed 
mechanism of how this increase of CTCs occur is that RT stimulates regeneration and 
growth of the tumor vascular system. While many schools of thought exist on how the 
tumor vasculature is improved, alternatively activated macrophages or M2 polarization 
is likely the most understood prominent and contributing factor. M2 macrophages are 
known to promote wound healing, vascular regenerative cytokines, and anti-
inflammatory functions, hindering the Th1 pro-inflammatory response required for 
successful antitumor immunity (197-199). Other immunosuppressive mechanisms 
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reported in preclinical metastatic melanoma studies include PD-1 agonism. This 
phenomenon was reported to occur via exosome mediated PDL1 shuttling to metastatic 
tumor sites in vivo (200). This information lends a partial explanation of the phenotype 
seen in the Figures 7-9 given that RT seemed to promote increased tumor burden and 
immune suppression in the lungs. The aforementioned findings provide a glimpse into 
the abyss of scientific discoveries in the field of RT, which have yet to be uncovered. 
Given the double-edged sword RT wields, clinical decisions on dosing and fractionation 
are made complicated beyond both measures, and current comprehension. Disease 
state specific RT regiments have shifted to hypofractionation, designed to ablate the RT 
treated tumor, given the clinical consequences of residual tumor in the primary site. 
Studies have shown that higher doses provide greater clinical protection due to 
disruption of the tumor vasculature, cytokine expression, and mitotic catastrophe (25, 
120, 155, 181, 182, 201, 202). This leaves clinicians with a delicate task of protecting 
normal tissue, yet delivering enough energy to the tumor site for curative intent. 
Experiments presented in this thesis are only a fraction of the work that went into 
investigating the RT regimens with positive or manageable effects on metastatic tumor 
burden. Anecdotal evidence from numerous in vivo experiments over the past five years 
indicate that the degree of metastatic tumor burden may alter RT dosages required for 
ablation of the primary treated site. This discovery was made when animals with 
increased tumor burden (metastatic models bearing two simultaneous tumors) required 
higher doses of RT at the primary tumor for ablation, as compared to the RT doses in 
animals harboring only a primary tumor (single tumor model). Additionally, a factor that 
further increases the complexity includes the likely variance in sensitivity to RT 
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mediated death of different cancer disease states. Given this knowledge, additional 
molecular diagnostic tools or biomarkers could aid in the guidance of personalized RT 
doses in given disease states. One example was an endonuclease called TREX1, 
which was only produced at lower RT doses and was found to dampen the RT cGAS-
STING mediated immune response. This occurred via degradation of cytosolic DNA by 
this endonuclease. In this study, hypofractionation led to improved immune responses, 
and correlated with decreased expression of the endonuclease TREX1, responsible for 
the loss of the cGAS-STING activation (17, 153). Logical next steps would be to validate 
this phenomenon in various cancer disease states, as it has potential to be used as a 
guiding clinical diagnostic tool for strategic delivery of RT. Altogether, RT has an infinite 
potential for the management of this disease state, however, methods for personalized 
RT dosing for the rare abscopal responses are yet to be elucidated in the clinic.  
 
Immunological Conferred Abscopal Response and Protection via Flagrp170 and 
RT Combination Treatment 
 
The collective data shown in this thesis indicates that Flagrp170 intratumoral treatments 
pair synergistically with RT. This was achieved by activating the immune response, at 
distant and untreated metastatic sites in both HNSCC and melanoma. While 
discernable and significant tumor control was observed in the HNSCC models, the B16 
metastatic melanoma model demonstrated questionable efficacy in tumor control with 
the addition of RT. Interestingly, in the SCC VII HNSCC model, we showed that 
previously cured animals with RT and Flagrp170 displayed a loss of immunological 
protection after being rechallenged with live tumor cells if CD4 T-cells were neutralized 
using antibody depletion. This finding is contrary to canonical school of thought in T-cell 
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tumor immunology, given that direct killing and cytotoxic effects are generalized with the 
activity and function of CD8 T-cells. Nonetheless, there is a growing body of evidence 
that shows that CD4 T-cells also direct cytotoxic killing via MHC II in melanoma 
preclinical and clinical ICB studies alike (203). In one study, animals bearing MMTV-
PyMT breast cancer tumors were treated with combination immunotherapy, then T-cells 
were sorted from peripheral tissues after treatment were infused into naive untreated 
animals bearing MMTV-PyMT tumors. The results of this experiment showed a strong 
dependence on CD4 T-cells maintaining tumor control as compared to CD8 T-cells. 
Furthermore, a phenotype of CD4+ CD44+ CD62L- CD69+ CD27lo Tbet+ T-cells were 
determined to be the specific subset responsible for the immunological protection 
conferred from the adoptive transfer. The group in this publication provided further 
evidence in elucidating this novel CD4+ T-cell subset by studying patients with 
advanced staged melanoma, treated with anti CTLA-4 and Gm-CSF. They found that 
patients who were responders to this treatment regimen expressed a high frequency of 
this CD4+ T-cell subset in peripheral blood, re-confirming this subsets importance in the 
field (204). Additionally, Flagrp170 is a danger signaling chimeric heat shock protein 
vaccine, that is capable of delivering whole tumor specific or associated proteins to 
APCs. This biological activity allows for a larger variety of epitopes of a given antigen to 
be displayed by the APC, not only by cross presentation on MHC I activating CD8 T-
cells, but also, conventional peptide presentation on MHC II as shown in this thesis 
(Figure 2). This indicates that CD4 T-cells may also play a sentinel role in reinvigorating 
the canonically assumed protective effector or memory effector functions of CD8 T-cells 
upon rechallenging with live tumor cells. This idea is evidenced in the literature from 
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reports showing that tumors with a scarcity of cross presenting DCs aid the CD4 T-cell 
response. This is due to the abundance of MHC II peptide expression, and the known 
increased MHC II peptide binding promiscuity as compared to MHC I (205). 
Furthermore, a study showed that long peptide vaccine-based immunotherapy in the 
melanoma setting also showed that CD4 T-cell activation was responsible for an 
efficient cytotoxic CD8 T- cell response in tumor rechallenge settings (206).  Given 
Flagrp170’s mechanism of action, it is scientifically possible for anyone of these 
aforementioned scenarios to be the rationale for our experimental observations.  
 
Flagrp170s Potential for Clinical Translation and Efficacy in HNSCC and Future 
Directions 
 
This therapy is well situated in the field given the dire need for an immune potentiating 
agent capable of vaccinating patients, and generating pre-existing immunity given the 
prevalence of ICB implementation in the clinic.  The Grp170 backbone is well reported 
to deliver whole proteins and therefore could provide the most diverse repertoire of 
peptide antigens of any given TAA or TSA. This will increase the probability of an MHC I 
or MHC II peptide binding of cognate CD8 or CD4 T-cells.  This in turn can benefit a 
wide variety of patients considering the vast heterozygosity of the HLA classes between 
patients, and the antigenic determinant effects caused by those differences. This means 
this therapy will serve as an off-the-shelf immunotherapeutic agent, which can provide 
personalized vaccination to the current antigens being expressed by patient’s tumors. 
This concept further analyzed, also means that if there is a loss of antigenicity, or 
patients become refractory after treatment, additional vaccinations may reorient the 
immune response to the new antigen targets expressed by the tumor. The data 
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presented in this thesis supports its implementation in the HNSCC RT setting, as it may 
reduce the required dose to achieve tumor volume control and long-term immunological 
memory. In particular, standard clinical RT regiments in HNSCC are within the range 
used in several of the HNSCC experiments presented, therefore its application in the 
neo-adjuvant therapy setting should be perused. Furthermore, our agent may aid in 
exploiting the therapeutic index of RT, achieving cures with lower doses and improving 
quality of life after treatment. Flagrp170’s potential in the HNSCC setting still requires 
further research. However, these data suggest its implementation in the clinic could lead 
to improvement of ICB response rates, reprograming of the tumor microenvironment, 
and increased abscopal effects resulting in higher cure rates and improved quality of life 




































































































Figure 1. Flagrp170 potentates the danger signals from radiation therapy 
(RT), synergizing to promote anti-tumor immunity.  
 
Single tumor model (SCC VII) combination of RT with Flagrp170 synergies for 
tumor control. Animals were treated once tumors reached 7-8mm in diameter with 
three fractions radiation therapy (RT) 2.5Gy consecutively and intra-tumoral 
injections of empty viral vector (CMV) or Flagrp170 for five doses q.a.d. (Figure 
1A) TIL analysis of CD8 T-cells at the tumor site (flow cytometry). (Figure 2B). TIL 
analysis of CD4 T-cells at the tumor site. (Figure 1C) Whole cell lysate (WCL) or 
OVA protein stimulation of splenocytes from SCC VII-OVA tumor bearing animals 
stimulated for 96-hours. (Figure 1D) Quantitative qPCR of immune related genes 
from SCC VII treated tumor tissue. (Figure 1E) RT dose response using 7.5Gy, 
15Gy, 30Gy total amounts delivered within three fractions, with either null virus or 
Flagrp170 for five doses q.a.d. (Figure 1F) Experiments representative of three or 
more independent experiments. Two-way ANOVA analysis was conducted with 
GraphPad Prism. Asterisks denotes statistical significance of: * P≤ 0.05, ** 




























































Figure 2. Flagrp170 promotes efficient APC priming and activation in draining 
lymph nodes 16hrs post-vaccination.  
Figure describing vaccination model and draining lymph node harvesting 16 post-vaccination in 




 conventional DCs receptor expression of 
CD80 and CD86 after vaccination (Figure 2B). CD8
+
 DCs analysis (flow cytometry) (Figure 
2C) CD103
+
 DC analysis (flow cytometry) (Figure 2D) Experiments representative of three or 
more independent experiments. Students T-test analysis was conducted with GraphPad Prism. 





































Reoccurrence RR p value 
RT+ Null 5/15 33.33% - RT (n=5) 5/5 - - 





































Figure 3. Radiation Alone and the Combination Treatment of Radiation and 
Flagrp170 Group Provided Protection in Established (5-6mm) SCC VII Tumors. 
  
Animals received no treatment (Control), or were treated with 30Gy of RT delivered 
in three fractions with a combined with empty viral vector (Null), or RT+Flagrp170 for 
five doses q.a.d. once tumors reached 5-6mm in diameter (Figure 3A). The 
RT+Flagrp170 treatment group provided improved tumor free for over four months 
as compared to RT+ Null group (Figure 3B). Animals that remained tumor free for 
two to four months after their treatment regimen were then rechallenged on the 
contralateral side (left) with 2x10
5 
cells/animal. RT+ Null group (n=5/15) survival was 
less than that of the RT+Flagrp170 (n=13/15) and a representative image is shown 
in (Figure 3C) A summary table with statistical analysis of tumor free survival after 
treatment using a Log-Rank Test and the relative risk (RR) of tumor reoccurrence 
after being rechallenged with live tumor cells is depicted in (Figure 3D) Animals 
rechallenged with SCC VII tumors had splenocytes harvested and stimulated ex-vivo 
with SCC VII whole cell lysates and then analyzed via flow cytometry. 
Representative samples show in (Figure 3E) and graphical representation of CD8 T-
cell analysis in (Figure 3F). Experiments representative of three or more 
independent experiments. Two-way ANOVA, Log rank, and relative risk analysis was 
conducted with GraphPad Prism. Asterisks denotes statistical significance of: * P≤ 











Figure 4. Head and neck tumor cells infected with Ad. Flagrp170 promotes 
immunity to tumor challenges via CD4 effector function. 
 
Immune antibody depletion of previously cured SCC VII and rechallenged tumor bearing 
animals showed that CD4
+





















































































































































Figure 5. SCC VII Contralateral tumor Model: Combination treatment of Flagrp170 
and RT therapy provides improved antitumor immunity at distant and metastatic 
sites.  
Animals had SCC VII tumors implanted in both flanks on day0 (2x10
5
 cells/right flank; 
1x10
5
 cells/left flank) and were treated with adenoviral intertumoral treatments of empty 
viral vector (CMV) or Flagrp170 for five doses q.a.d. once tumors reached 5-6mm.  
Radiation therapy was also delivered with on the first day of viral treatments with three 
fractions of 10 Gys on days 5,6, and 7. (Figure 5A) Primary and contralateral tumor 
growth curve of SCC VII tumor model. (Figure 5B) Flow cytometry of TILs in the 
contralateral tumor. (Figure 5C) TIL analysis of myeloid derived suppressor cells CD11b+ 
gating for analysis of Ly6C and Ly6G. (Figure 5D) Splenocyte whole tumor cell lysate 
activation assay of tumor bearing animals. (Figure 5E) Analysis of immune related genes 
of at the contralateral tumor site. (Figure 5F) Experiments representative of three or more 
independent experiments. Two-way ANOVA analysis was conducted with GraphPad 




































































































































































Figure 6. Combination treatment of Flagrp170 and RT therapy provides 
improved anti-tumor immunity against a naturally metastatic HNSCC model.  
 
Animals had MOC II cells implanted subcutaneously on Day 0. Intertumoral 
treatments of empty viral vector (null) or Flagrp170 for five doses q.a.d. began 
once the primary tumors reached 5-6mm.  Radiation therapy was also delivered 
with on the first day of viral treatments with three fractions of 2.5Gys on days 5,6, 
and 7. (Figure 6A) Analysis of immune related genes via qPCR from MOC II 
treated tumors (Figure 6B) Primary tumor growth curve of MOC II-Luc tumor 
model treated with higher dose RT, (10Gy x3) for long term analysis of survival. 
(Figure 6C) Tumor growth monitored via luciferase activity in vivo using an IVIS 
(Figure 6D) Experiments representative of two or more independent experiments. 
Two-way ANOVA analysis was conducted with GraphPad Prism. Asterisks 














































Figure 7. B16 Melanoma Primary and Lung Metastatic Model 
C57/B6 mice were subcutaneously injected with B16 (2x10
5
 cells/animal) for a primary 
tumor on day 0, then had an intravenous injection of B16 (1x10
5
 per/animal) cells on day 3. 
Animals received treatment once the primary tumor reached 5-6mm with radiation 30Gys 
fractionated into three doses, and five doses of Flagrp170 2x10
8 
PFU/animal delivered 
q.a.d. (Figure 7A) Representative ex vivo gross observational image of lungs from tumor 
bearing mice. (Figure 7B) Lung nodules of B16 colonies were counted in a blinded fashion 
and then lungs were digested and a single cell suspension was prepared for TIL isolation 
and seeding for a clonogenic assay (1x10
4
 cells/well). (Figure 7C) Two-way ANOVA 
analysis was conducted with GraphPad Prism. Asterisks denotes statistical significance of: 




















Figure 8. Combination Therapy Induces Increased T-cell Activation 
Concomitantly with Strong Inhibitory Signals at the Tumor Site.   




 T-cell IFN-γ production from the primary tumor. (Figure 
8A) Tumor tissue was obtained from the primary (treated) tumor and analyzed via 
qPCR for expression of various immunological genes. IFN-γ increased in the 
combination group while granzyme B expression decreased and IL-10, PD-1, and 


















Figure 9. Metastatic Site Experienced Increased Immune Stimulation and while 
Undergoing Robust Inhibitory Signals. 
 




 T-cell IFN-γ production from the metastatic tumor site 
(lung). (Figure 9A) Lung tissue was harvested from animals and used for qPCR 
analysis of gene expression at the tissue level.  IFN-γ and granzyme B expression were 
increased in the combination treatment groups indicating a strong inflammatory 
response. IFN-Β induction seemed to be driven by groups that included RT as a 
treatment modality. Inhibitory markers (PD-1, PDL1, PDL2), tolerogenic transcription 
factors (FoxP3), and soluble factors like IL-10 were most present in the combination 
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